WD-40 (WDFC - Free Report) came out with quarterly earnings of $2.33 per share, beating the Zacks Consensus Estimate of $1.58 per share. This compares to earnings of $1.54 per share a year ago. These figures are adjusted for non-recurring items.
This quarterly report represents an earnings surprise of +47.47%. A quarter ago, it was expected that this maintenance and cleaning product company would post earnings of $1.39 per share when it actually produced earnings of $1.5, delivering a surprise of +7.91%.
Over the last four quarters, the company has surpassed consensus EPS estimates three times.
WD-40, which belongs to the Zacks Consumer Products - Staples industry, posted revenues of $195.12 million for the quarter ended May 2026, surpassing the Zacks Consensus Estimate by 13.57%. This compares to year-ago revenues of $156.91 million. The company has topped consensus revenue estimates two times over the last four quarters.
The sustainability of the stock's immediate price movement based on the recently-released numbers and future earnings expectations will mostly depend on management's commentary on the earnings call.
WD-40 shares have added about 25.2% since the beginning of the year versus the S&P 500's gain of 9.3%.
What's Next for WD-40?While WD-40 has outperformed the market so far this year, the question that comes to investors' minds is: what's next for the stock?
There are no easy answers to this key question, but one reliable measure that can help investors address this is the company's earnings outlook. Not only does this include current consensus earnings expectations for the coming quarter(s), but also how these expectations have changed lately.
Empirical research shows a strong correlation between near-term stock movements and trends in earnings estimate revisions. Investors can track such revisions by themselves or rely on a tried-and-tested rating tool like the Zacks Rank, which has an impressive track record of harnessing the power of earnings estimate revisions.
Ahead of this earnings release, the estimate revisions trend for WD-40 was mixed. While the magnitude and direction of estimate revisions could change following the company's just-released earnings report, the current status translates into a Zacks Rank #3 (Hold) for the stock. So, the shares are expected to perform in line with the market in the near future. You can see the complete list of today's Zacks #1 Rank (Strong Buy) stocks here.
It will be interesting to see how estimates for the coming quarters and the current fiscal year change in the days ahead. The current consensus EPS estimate is $1.62 on $173.1 million in revenues for the coming quarter and $5.99 on $655 million in revenues for the current fiscal year.
Investors should be mindful of the fact that the outlook for the industry can have a material impact on the performance of the stock as well. In terms of the Zacks Industry Rank, Consumer Products - Staples is currently in the bottom 19% of the 250 plus Zacks industries. Our research shows that the top 50% of the Zacks-ranked industries outperform the bottom 50% by a factor of more than 2 to 1.
Newell Brands (NWL - Free Report) , another stock in the same industry, has yet to report results for the quarter ended June 2026. The results are expected to be released on July 31.
This consumer products company is expected to post quarterly earnings of $0.19 per share in its upcoming report, which represents a year-over-year change of -20.8%. The consensus EPS estimate for the quarter has remained unchanged over the last 30 days.
Newell Brands' revenues are expected to be $1.96 billion, up 1.5% from the year-ago quarter.
WD-40 Company zveřejnila výsledky za 3. fiskální čtvrtletí 2026, ale v přiloženém textu nejsou uvedeny žádné konkrétní finanční údaje ani komentář k výkonnosti.
WD-40 Company (WDFC) Q3 2026 Earnings Call July 9, 2026 5:00 PM EDT
Company Participants
Wendy Kelley - Director of Investor Relations & Corporate Communications
Steven Brass - CEO, President & Director
Sara Hyzer - CFO, VP of Finance & Treasurer
Conference Call Participants
Aaron Reed - Northcoast Research Partners, LLC
Michael Baker - D.A. Davidson & Co., Research Division
David Shakno - William Blair & Company L.L.C., Research Division
Daniel Rizzo - Jefferies LLC, Research Division
Linda Weiser - Water Tower Research LLC
Presentation
Operator
Good day, and welcome to WD-40 Company's Third Quarter Fiscal Year 2026 Earnings Conference Call. Today's call is being recorded. [Operator Instructions]
I will now turn the call over to Wendy Kelley, Vice President, Stakeholder and Investor Engagement. Please go ahead.
Wendy Kelley
Director of Investor Relations & Corporate Communications
Thank you, and good afternoon. Thank you for joining us today. On our call today are WD-40 Company's President and Chief Executive Officer, Steve Brass; and Vice President and Chief Financial Officer, Sara Hyzer.
In addition to today's discussion, we encourage investors to review our earnings presentation, press release and Form 10-Q for the period ending May 31, 2026, available on our Investor Relations website at investor.wd40company.com. A replay and transcript of today's call will also be posted shortly. We will discuss certain non-GAAP measures today. Reconciliations to GAAP results are available in our SEC filings and earnings materials. Today's call also includes forward-looking statements. Actual results may differ materially. Please refer to the risk factors in our SEC filings for more information. Finally, please note that all information presented is current as of July 9, 2026, and we undertake no obligation to update forward-looking statements.
With that, I'll turn the call over to Steve.
Steven Brass
CEO, President & Director
Thanks, Wendy, and thanks to everyone for joining us
In the latest close session, Coca-Cola (KO - Free Report) was down 1.02% at $82.55. The stock fell short of the S&P 500, which registered a gain of 0.81% for the day. Meanwhile, the Dow gained 0.27%, and the Nasdaq, a tech-heavy index, added 1.3%.
Coming into today, shares of the world's largest beverage maker had lost 0.23% in the past month. In that same time, the Consumer Staples sector gained 3.31%, while the S&P 500 gained 1.13%.
The investment community will be closely monitoring the performance of Coca-Cola in its forthcoming earnings report. The company is scheduled to release its earnings on July 28, 2026. In that report, analysts expect Coca-Cola to post earnings of $0.92 per share. This would mark year-over-year growth of 5.75%. Our most recent consensus estimate is calling for quarterly revenue of $13.05 billion, up 4.15% from the year-ago period.
For the entire fiscal year, the Zacks Consensus Estimates are projecting earnings of $3.26 per share and a revenue of $49.33 billion, representing changes of +8.67% and +3%, respectively, from the prior year.
Investors should also take note of any recent adjustments to analyst estimates for Coca-Cola. Recent revisions tend to reflect the latest near-term business trends. Consequently, upward revisions in estimates express analysts' positivity towards the business operations and its ability to generate profits.
Our research reveals that these estimate alterations are directly linked with the stock price performance in the near future. We developed the Zacks Rank to capitalize on this phenomenon. Our system takes these estimate changes into account and delivers a clear, actionable rating model.
The Zacks Rank system, ranging from #1 (Strong Buy) to #5 (Strong Sell), possesses a remarkable history of outdoing, externally audited, with #1 stocks returning an average annual gain of +25% since 1988. Over the past month, there's been no change in the Zacks Consensus EPS estimate. Coca-Cola currently has a Zacks Rank of #2 (Buy).
Digging into valuation, Coca-Cola currently has a Forward P/E ratio of 25.57. This valuation marks a premium compared to its industry average Forward P/E of 20.33.
We can additionally observe that KO currently boasts a PEG ratio of 3.33. The PEG ratio is akin to the commonly utilized P/E ratio, but this measure also incorporates the company's anticipated earnings growth rate. The Beverages - Soft drinks industry currently had an average PEG ratio of 2.17 as of yesterday's close.
The Beverages - Soft drinks industry is part of the Consumer Staples sector. At present, this industry carries a Zacks Industry Rank of 108, placing it within the top 44% of over 250 industries.
The strength of our individual industry groups is measured by the Zacks Industry Rank, which is calculated based on the average Zacks Rank of the individual stocks within these groups. Our research shows that the top 50% rated industries outperform the bottom half by a factor of 2 to 1.
Be sure to use Zacks.com to monitor all these stock-influencing metrics, and more, throughout the forthcoming trading sessions.
Amazon (AMZN - Free Report) closed at $247.04 in the latest trading session, marking a +1.4% move from the prior day. The stock's change was more than the S&P 500's daily gain of 0.81%. On the other hand, the Dow registered a gain of 0.27%, and the technology-centric Nasdaq increased by 1.3%.
Prior to today's trading, shares of the online retailer had gained 2.36% outpaced the Retail-Wholesale sector's gain of 0.24% and the S&P 500's gain of 1.13%.
Market participants will be closely following the financial results of Amazon in its upcoming release. The company is predicted to post an EPS of $1.82, indicating a 8.33% growth compared to the equivalent quarter last year. At the same time, our most recent consensus estimate is projecting a revenue of $196.9 billion, reflecting a 17.41% rise from the equivalent quarter last year.
For the entire fiscal year, the Zacks Consensus Estimates are projecting earnings of $8.86 per share and a revenue of $826.36 billion, representing changes of +23.57% and +15.26%, respectively, from the prior year.
Investors should also note any recent changes to analyst estimates for Amazon. Such recent modifications usually signify the changing landscape of near-term business trends. As such, positive estimate revisions reflect analyst optimism about the business and profitability.
Our research shows that these estimate changes are directly correlated with near-term stock prices. We developed the Zacks Rank to capitalize on this phenomenon. Our system takes these estimate changes into account and delivers a clear, actionable rating model.
The Zacks Rank system ranges from #1 (Strong Buy) to #5 (Strong Sell). It has a remarkable, outside-audited track record of success, with #1 stocks delivering an average annual return of +25% since 1988. The Zacks Consensus EPS estimate has moved 0.39% higher within the past month. Amazon is holding a Zacks Rank of #2 (Buy) right now.
In terms of valuation, Amazon is currently trading at a Forward P/E ratio of 27.48. Its industry sports an average Forward P/E of 16.7, so one might conclude that Amazon is trading at a premium comparatively.
Investors should also note that AMZN has a PEG ratio of 1.59 right now. Comparable to the widely accepted P/E ratio, the PEG ratio also accounts for the company's projected earnings growth. As of the close of trade yesterday, the Internet - Commerce industry held an average PEG ratio of 1.04.
The Internet - Commerce industry is part of the Retail-Wholesale sector. This group has a Zacks Industry Rank of 187, putting it in the bottom 24% of all 250+ industries.
The Zacks Industry Rank assesses the vigor of our specific industry groups by computing the average Zacks Rank of the individual stocks incorporated in the groups. Our research shows that the top 50% rated industries outperform the bottom half by a factor of 2 to 1.
Don't forget to use Zacks.com to keep track of all these stock-moving metrics, and others, in the upcoming trading sessions.
Na Microsoft byla podána hromadná žaloba kvůli údajné podvodné praxi kolem Azure a Copilotu. Akcie po výsledcích za fiskální 2. čtvrtletí zveřejněných 28. ledna 2026 klesly téměř o 10 %.
, /PRNewswire/ -- Pomerantz LLP announces that a class action lawsuit has been filed against Microsoft Corporation ("Microsoft" or the "Company") (NASDAQ: MSFT). Such investors are advised to contact Danielle Peyton at [email protected] or 646-581-9980, (or 888.4-POMLAW), toll-free, Ext. 7980. Those who inquire by e-mail are encouraged to include their mailing address, telephone number, and the number of shares purchased.
The class action concerns whether Microsoft and certain of its officers and/or directors have engaged in securities fraud or other unlawful business practices.
You have until August 11, 2026, to ask the Court to appoint you as Lead Plaintiff for the class if you purchased or otherwise acquired Microsoft securities during the Class Period. A copy of the Complaint can be obtained at www.pomerantzlaw.com.
[Click here for information about joining the class action]
On January 28, 2026, Microsoft announced disappointing results for its fiscal second quarter ended December 31, 2025. First, during the quarter Microsoft's Azure growth had slowed suddenly and fallen below analyst expectations. During the related earnings call, CFO Amy E. Hood revealed that the slower Azure growth was primarily due to computational capacity constraints, as Microsoft had diverted CPU and GPU capacity to Copilot applications and AI-related R&D. Second, Microsoft revealed that its capital expenditures had increased to $37.5 billion during the quarter, causing Microsoft's capital expenditures for the first six months of its fiscal 2026 to increase to $72.4 billion compared to $88.2 billion for all of Microsoft's fiscal 2025. Third, Microsoft revealed, for the first time, that the number of paid Microsoft 365 Copilot seats totaled only 15 million to date, materially below analyst estimates and a fraction of the more than 450 million commercial Microsoft 365 users.
On this news, the price of Microsoft stock fell nearly 10%.
Then, on February 3, 2026, The Wall Street Journal revealed, in an article titled "Microsoft's Pivotal AI Product Is Running Into Big Problems," that severe challenges and functionality issues had plagued Microsoft's Copilot offerings, leading to Copilot losing market share during the Class Period to competing products such as Google's Gemini. The price of Microsoft stock continued to fall in the days after Microsoft's second quarter 2026 earnings announcement as the market continued to digest the adverse news and sources such as The Wall Street Journal revealed new adverse information.
Thereafter, on March 17, 2026, The Wall Street Journal revealed in an article titled "Microsoft Seeks More Coherence in AI Efforts With Copilot Reorganization" that Microsoft was reorganizing its Copilot product teams to unify commercial and consumer versions partly in response to the challenges revealed by The Wall Street Journal's prior reporting on Copilot's problem-plagued development and disappointing customer adoption.
On this news, the price of Microsoft stock continued to fall.
Pomerantz LLP, with offices in New York, Chicago, Los Angeles, London, Paris, and Tel Aviv, is acknowledged as one of the premier firms in the areas of corporate, securities, and antitrust class litigation. Founded by the late Abraham L. Pomerantz, known as the dean of the class action bar, Pomerantz pioneered the field of securities class actions. Today, more than 85 years later, Pomerantz continues in the tradition he established, fighting for the rights of the victims of securities fraud, breaches of fiduciary duty, and corporate misconduct. The Firm has recovered numerous multimillion-dollar damages awards on behalf of class members. See www.pomlaw.com.
Attorney advertising. Prior results do not guarantee similar outcomes.
Nvidia zrychlila výrobu architektury Vera Rubin, která má umožnit trénovat AI modely s o 75 % méně GPU a snížit náklady na tokeny inference až o 90 % ve srovnání s Blackwellem.
Elon Musk's space transportation, satellite internet connectivity, and artificial intelligence (AI) company, Space Exploration Technologies (SPCX +2.60%), went public on June 12, and opened that trading session at $150 per share. In the days that followed, the stock soared to an all-time high of $225.64, but it has since plunged back to about $150 as investors grapple with its sky-high valuation.
SpaceX has a market capitalization of $2 trillion as I write this, and with just $19.3 billion in trailing-12-month revenue, that gives it a price-to-sales (P/S) ratio of 103. That's 16 times more expensive than the average for the tech-heavy Nasdaq-100 index. As a result, I won't be surprised if SpaceX declines from here.
If I had $10,000 to invest in one stock for my diversified portfolio, I'd definitely consider an alternative. Here's why Nvidia (NVDA 0.62%) might be a much better buy than SpaceX for the long term.
Image source: Nvidia.
Vera Rubin is in full production Nvidia supplies the world's best graphics processing units (GPUs) for data centers, and its chips are still the main providers of parallel processing power for AI training and inference workloads. The company's dominance in that niche started in 2022 with the H100 GPU, which was built on the Hopper architecture. But in the years since, Nvidia has launched its Blackwell and Blackwell Ultra GPU architectures, the latter of which can deliver up to 50 times better performance than Hopper-based chips in certain configurations.
And the chipmaker just upped the ante again. It has ramped its newest architecture, Vera Rubin, up to full production and will begin shipping them in commercial quantities in the coming months. That new platform includes the Rubin GPU, the Vera central processing unit (CPU), copious memory, and a series of upgraded networking components, which combine to provide another big leap in AI computing performance. In fact, Nvidia says this new architecture will allow developers to train AI models with 75% fewer GPUs, while reducing inference token costs by up to 90% compared to its Blackwell processors.
Inference tokens represent the text, symbols, and images produced by an AI model in response to a query. So to simplify what the company is saying, Vera Rubin will dramatically reduce the cost of using AI software, which could fuel a surge in its adoption. It will also make AI providers like OpenAI and Anthropic more profitable, which could lead to even more demand for Nvidia's chips.
Vera Rubin is almost certain to be Nvidia's most successful product platform ever. According to CEO Jensen Huang, every frontier model company plans to adopt it at launch. That was not the case for Blackwell when it debuted.
Nvidia is on track for another record year Nvidia generated $81.6 billion in revenue during its fiscal 2027 first quarter (which ended April 26), representing year-over-year growth of 85%. Its data center business accounted for $75.2 billion of that total, and it grew at an even faster rate of 92%.
Analysts estimate that Nvidia could generate $392 billion in total revenue during its fiscal 2027, and a whopping $554 billion in its fiscal 2028. If the company continues to grow at this pace, it could be bringing in as much money as Walmart -- the world's biggest retailer -- within a few years.
Today's Change
(
-0.62
%) $
-1.27
Current Price
$
202.85
However, there are risks ahead. Concerns are mounting about the sustainability of the AI infrastructure boom, as shortages of GPUs and high-bandwidth memory have significantly driven up the cost of building data centers. AI software providers like Anthropic and Microsoft have implemented passive price increases this year in an effort to pass some of those additional costs to their customers -- who have not responded well to the moves.
The chief operating officer at Uber Technologies recently said it's becoming harder to justify AI spending, after his company burned through its entire 2026 AI budget in just four months. It appears he isn't alone, because a recent survey by UBS Group suggests 60% of businesses are now opting for cheaper AI models that use less computing power. That might be bad news for semiconductor demand going forward.
Buyers today are getting a great price for Nvidia stock While there are certainly risks ahead, I would argue that Nvidia's attractive valuation makes those risks worth accepting. The stock is trading at a price-to-earnings (P/E) ratio of 30.2, which is half its 10-year average of 61.6.
It's also cheaper than the Nasdaq-100 index, which has a P/E ratio of 35.2, suggesting the chipmaker is undervalued compared to its big-tech peers.
Looking ahead, the consensus among Wall Street analysts is that Nvidia's earnings will grow to $12.76 in its fiscal 2028, giving its stock a forward P/E ratio of just 15.4.
NVDA PE Ratio data by YCharts.
I'm not suggesting this will happen, but if Wall Street's fiscal 2028 estimate proves to be accurate, Nvidia stock would have to double over the next 18 months just to maintain its current P/E ratio, and quadruple to trade in line with its 10-year average P/E.
Of course, the picture will look very different if the AI industry starts buying fewer GPUs. However, I think Nvidia's valuation leaves quite a bit of room for error -- especially if we're comparing it to SpaceX, which is objectively extremely overvalued right now.
Disney is exploring making some content on its namesake streamer free to watch. Stefano Facchin/Alessio Morgese/NurPhoto via Getty Images Disney is exploring making some of its streaming content available at an unbeatable price: free.
The Mouse House is discussing making some content accessible on Disney+ without a paywall, according to two people familiar with the matter.
Product and tech chief Adam Smith spoke about enabling free-tier content during a streaming town hall on Thursday afternoon, one staffer said. Smith didn't share a timeline for this initiative or a sense of the scope, this person added.
A person familiar with Disney's streaming strategy said these talks are part of an ongoing discussion about concepts to better serve fans.
Currently, the Disney+ and Hulu bundle costs $12.99 a month with ads or $19.99 without ads at full price.
Free streaming services like YouTube have become popular with audiences, generating significant growth in viewership share on US-based TVs compared to their paid peers, according to Nielsen data. The three largest free streamers accounted for 18.7% of watch time on US TVs in April, up from 16.8% a year earlier and 12.7% in April 2024.
As paid streamers have raised prices, consumers have increasingly sought out free content on YouTube and on ad-supported services like Tubi and The Roku Channel. (Tubi parent Fox is planning to double down on free streaming by buying Roku for $22 billion.)
A free tier could help Disney+ stand out among paid streamers. Apple TV and Paramount+ let users sample some full episodes, but paid streaming services generally don't have robust free offerings.
Disney and its Hollywood peers are also looking to boost engagement by embracing new formats like short-form video, podcasts, and micro dramas, which are bite-sized vertical shows.
In recent months, Disney has added vertical clips to its flagship streaming app, as has Paramount+. Disney CEO Josh D'Amaro has told staffers he's prioritizing "product and technology innovation" in streaming.
Netflix announced this week that it's adding 3- to 20-minute videos next month from publishers like BuzzFeed Studios, Condé Nast, Hearst Magazines, Penske Media, and People Inc. The streaming giant made a major move into video podcasts earlier this year and has also dabbled in vertical video.
Read next
James Faris You're currently following this author! Want to unfollow? Unsubscribe via the link in your email.
BlackRock uzavřel poslední seanci na 1 019,68 USD, což znamenalo denní růst o 2,96 % a lepší výkon než S&P 500. Investoři sledují výsledky, které firma zveřejní 15. července 2026.
BlackRock (BLK - Free Report) ended the recent trading session at $1,019.68, demonstrating a +2.96% change from the preceding day's closing price. The stock's performance was ahead of the S&P 500's daily gain of 0.81%. Elsewhere, the Dow gained 0.27%, while the tech-heavy Nasdaq added 1.3%.
Shares of the investment firm witnessed a loss of 2.01% over the previous month, trailing the performance of the Finance sector with its gain of 4.07%, and the S&P 500's gain of 1.13%.
The investment community will be paying close attention to the earnings performance of BlackRock in its upcoming release. The company is slated to reveal its earnings on July 15, 2026. The company's upcoming EPS is projected at $12.54, signifying a 4.07% increase compared to the same quarter of the previous year. Meanwhile, the latest consensus estimate predicts the revenue to be $6.75 billion, indicating a 24.51% increase compared to the same quarter of the previous year.
Looking at the full year, the Zacks Consensus Estimates suggest analysts are expecting earnings of $53.46 per share and revenue of $28.08 billion. These totals would mark changes of +11.17% and +15.97%, respectively, from last year.
It's also important for investors to be aware of any recent modifications to analyst estimates for BlackRock. Such recent modifications usually signify the changing landscape of near-term business trends. As such, positive estimate revisions reflect analyst optimism about the business and profitability.
Our research demonstrates that these adjustments in estimates directly associate with imminent stock price performance. We developed the Zacks Rank to capitalize on this phenomenon. Our system takes these estimate changes into account and delivers a clear, actionable rating model.
The Zacks Rank system, which varies between #1 (Strong Buy) and #5 (Strong Sell), carries an impressive track record of exceeding expectations, confirmed by external audits, with stocks at #1 delivering an average annual return of +25% since 1988. Over the past month, the Zacks Consensus EPS estimate has shifted 0.92% upward. Right now, BlackRock possesses a Zacks Rank of #3 (Hold).
Valuation is also important, so investors should note that BlackRock has a Forward P/E ratio of 18.53 right now. This denotes a premium relative to the industry average Forward P/E of 11.41.
We can also see that BLK currently has a PEG ratio of 1.27. Comparable to the widely accepted P/E ratio, the PEG ratio also accounts for the company's projected earnings growth. Financial - Investment Management stocks are, on average, holding a PEG ratio of 1.03 based on yesterday's closing prices.
The Financial - Investment Management industry is part of the Finance sector. This industry, currently bearing a Zacks Industry Rank of 181, finds itself in the bottom 27% echelons of all 250+ industries.
The Zacks Industry Rank evaluates the power of our distinct industry groups by determining the average Zacks Rank of the individual stocks forming the groups. Our research shows that the top 50% rated industries outperform the bottom half by a factor of 2 to 1.
Don't forget to use Zacks.com to keep track of all these stock-moving metrics, and others, in the upcoming trading sessions.
PepsiCo ve 2. čtvrtletí zvýšila tržby na téměř 24,2 miliardy USD a čistý zisk podle GAAP na téměř 2,99 miliardy USD, ale akcie po výsledcích klesly o více než 3 %.
Investors weren’t too eager to take a swig of PepsiCo (PEP 3.26%) after the beverage and snacks giant reported second-quarter results early on Thursday. This, despite headline figures that — depending on which consensus numbers are used — beat analyst estimates. The company’s shares slid by more than 3% that trading session, contrasting poorly with the 0.8% rise of the bellwether S&P 500 index.
Let’s tuck into PepsiCo’s quarter to find out why it was such a flat, warm can of soda for many market players.
Image source: Getty Images.
Where’s the fizz?During the quarter, PepsiCo’s net revenue was just under $24.2 billion, up 6% year over year. The company’s net income under generally accepted accounting principles (GAAP) grew much more robustly, doubling and then some to almost $2.99 billion from the year-ago profit of $1.26 billion. Yet on a per-share, non-GAAP (adjusted, or “core” in company parlance) basis, net income only inched up by 4% to $2.20.
This meant a pair of beats for PepsiCo, though these were modest. On average, analysts tracking the stock were modeling net revenue of $23.9 billion and core earnings per share (EPS) of $2.19.
Despite the growth in key fundamentals, other metrics were lower this quarter. The company’s largest single market remains its native North America, so weakness there is always cause for concern. Second-quarter sales in the company’s food (i.e., snacks) business there fell by 2% year over year. And while revenue from its beverages rose by 7%, much of this was due to recently integrated acquisitions and partnerships. The latter included a deal with Celsius (CELH 0.24%) to distribute that company’s hotly popular drink line Alani Nu.
It’s revealing that overall volumes for North America beverages sank in spite of this, falling by 4%. And, when stripping out acquisitions and divestitures from the mix, that drinks unit saw only a 1% organic revenue gain.
In the conference call discussing the results, PepsiCo CEO Ramon Laguarta attributed the U.S. declines to changes in consumer behavior. He speculated that the soaring price of gasoline was affecting traffic at convenience stores. This is a major sales channel for the company as items like its Pepsi and Doritos are often impulse buys for customers filling their tanks or taking a rest from driving.
International flavorOn a brighter note or two, PepsiCo performed better in markets abroad. Its international beverages business saw gains in both volume (5%) and, especially, reported revenue (11%, or 9% when adjusted for foreign currency exchange). Better, since those acquisitions were concentrated on U.S. products, that overseas growth was entirely organic.
The company’s snacks also proved to be popular outside our borders. Standouts in this category were Asia Pacific and Latin America foods, which saw reported revenue growth of 15% and 12%, respectively.
So basically, PepsiCo had two diverging trajectories — the sluggishness of the North America operations, and the dynamism of its international efforts. The latter should help the company achieve growth in the coming quarters — it reiterated its guidance for full-year 2026, forecasting organic revenue growth of 2% to 4% over 2025, with a rise in core, constant-currently EPS of 4% to 6%.
Importantly for this Dividend King — PepsiCo is one of the rare companies that has declared dividend raises at least once annually for a minimum of 50 years running — it expects to distribute $7.9 billion in shareholder payouts during the year. That’s up from the $7.6 billion it spent last year. Management also intends to devote $1 billion to share buybacks.
Potential yield trapI think PepsiCo still has some way to go in order to become an investor favorite again. Those slumps in the North America business are concerning and, outside of the unlikely possibility that international growth rockets much higher, softness in that market will negatively affect both the fundamentals and investor perception of the business.
A longer-term issue for PepsiCo is that, in many ways, it’s a poster boy for unhealthy food and drink consumption. That served it well for decades, but this century’s trend — at least on our shores — is towards more considered, healthier eating and quaffing. Yes, PepsiCo has diet/no-sugar drinks and moderately better-for-you snacks. But it’s still anchored by, and strongly identified with, goodies like Pepsi and Cheetos.
As for shareholder remuneration, PepsiCo is not only a Dividend King, its payout is bubbling into high-yield territory at almost 4.3%. This, however, is largely due to a weakened share price, which, after earnings, was teasing its one-year low.
While the dividend might be an attractive draw for investors hungry for yield or sniffing around for a bargain, that wouldn’t tip me into buying the stock. I don’t see either North America beverages or food improving much, and PepsiCo’s wares aren’t popular enough abroad to offset this significantly.
Caterpillar uzavřel poslední obchodní den na 938,39 USD, což bylo o 1,02 % méně než předchozí den, zatímco S&P 500 vzrostl o 0,81 %. Akcie ale za poslední měsíc přidaly 10,74 %.
Caterpillar (CAT - Free Report) closed the most recent trading day at $938.39, moving -1.02% from the previous trading session. This move lagged the S&P 500's daily gain of 0.81%. Meanwhile, the Dow gained 0.27%, and the Nasdaq, a tech-heavy index, added 1.3%.
Shares of the construction equipment company witnessed a gain of 10.74% over the previous month, beating the performance of the Industrial Products sector with its gain of 0.86%, and the S&P 500's gain of 1.13%.
The upcoming earnings release of Caterpillar will be of great interest to investors. The company's earnings per share (EPS) are projected to be $6.21, reflecting a 31.57% increase from the same quarter last year. Meanwhile, our latest consensus estimate is calling for revenue of $19.08 billion, up 15.17% from the prior-year quarter.
For the full year, the Zacks Consensus Estimates are projecting earnings of $24.71 per share and revenue of $76.56 billion, which would represent changes of +29.64% and +13.28%, respectively, from the prior year.
It's also important for investors to be aware of any recent modifications to analyst estimates for Caterpillar. Recent revisions tend to reflect the latest near-term business trends. As such, positive estimate revisions reflect analyst optimism about the business and profitability.
Empirical research indicates that these revisions in estimates have a direct correlation with impending stock price performance. To capitalize on this, we've crafted the Zacks Rank, a unique model that incorporates these estimate changes and offers a practical rating system.
The Zacks Rank system, ranging from #1 (Strong Buy) to #5 (Strong Sell), possesses a remarkable history of outdoing, externally audited, with #1 stocks returning an average annual gain of +25% since 1988. Over the past month, there's been a 0.06% rise in the Zacks Consensus EPS estimate. Caterpillar presently features a Zacks Rank of #2 (Buy).
Investors should also note Caterpillar's current valuation metrics, including its Forward P/E ratio of 38.37. Its industry sports an average Forward P/E of 15.52, so one might conclude that Caterpillar is trading at a premium comparatively.
We can also see that CAT currently has a PEG ratio of 1.87. The PEG ratio is akin to the commonly utilized P/E ratio, but this measure also incorporates the company's anticipated earnings growth rate. As the market closed yesterday, the Manufacturing - Construction and Mining industry was having an average PEG ratio of 1.63.
The Manufacturing - Construction and Mining industry is part of the Industrial Products sector. At present, this industry carries a Zacks Industry Rank of 72, placing it within the top 30% of over 250 industries.
The Zacks Industry Rank assesses the vigor of our specific industry groups by computing the average Zacks Rank of the individual stocks incorporated in the groups. Our research shows that the top 50% rated industries outperform the bottom half by a factor of 2 to 1.
Keep in mind to rely on Zacks.com to watch all these stock-impacting metrics, and more, in the succeeding trading sessions.
Micron Technology oznámila na začátku července dlouhodobé smlouvy na dodávky pamětí s General Motors a Fordem, přičemž jde o dvě z 16 dohod zmíněných při posledním hovoru s investory. Tyto víceleté kontrakty mohou firmě zajistit viditelnější poptávku před další výsledkovou zprávou.
Most of the attention on Micron Technology (MU +4.55%) sits on high-bandwidth memory and the artificial intelligence data center boom. That story is real, but it hides a different shift in how the company sells its products -- a shift that could shape the next earnings report more than any single chip.
Micron is signing long-term supply agreements In the first week of July, Micron announced two strategic customer agreements within six days of each other. A strategic customer agreement is, in plain terms, a promise from a buyer to keep buying.
On July 1, it signed a deal with General Motors to secure a long-term supply of memory for the automaker's next vehicle platforms. On July 6, Micron announced a similar pact with Ford Motor Company.
Image source: Getty Images.
Buried in both press releases is the detail that matters most. Each agreement is described as "one of the 16" discussed on Micron's fiscal third-quarter conference call. So the company has told investors it has a stack of these deals and has started revealing them one at a time. That drumbeat of announcements gives Micron a reason to stay in the news between now and its next report.
Why the automotive deals matter These are not glamorous AI chips. General Motors is locking in a supply of LPDRAM, NOR, and UFS NAND -- the memory that runs in-cabin screens and driver-assistance systems. Cars carry the kind of memory once reserved for phones and servers, and each model can stay in production for years, so a single win can feed orders long after the deal is signed.
What makes the deals valuable is their shape: multiyear commitments tied to Micron's $2 billion modernization of its Manassas, Virginia, fab.
Memory has long been a boom-and-bust business, priced like a commodity. Contracts that pin down volume across a car's production life turn some of that swing into something closer to a backlog. For a company investors treat as a cyclical bet, contracted demand is a quiet form of insurance on an investment.
Today's Change
(
4.55
%) $
43.22
Current Price
$
992.02
The risks investors should weigh None of these agreements discloses price or volume, so the financial impact remains unknown until it shows up in the results. Auto production can soften, and a broad memory downturn would pressure margins. The stock has climbed a long way, which raises the bar for any surprise.
The catalyst is not a number. If Micron keeps converting that list of 16 agreements into signed deals before its fiscal fourth-quarter report, I think the market gets a running preview of demand that most cyclical suppliers cannot offer. Investors who own the stock or watch it should track the number of these agreements as a real-time signal ahead of earnings.
Occidental Petroleum (OXY - Free Report) closed at $52.30 in the latest trading session, marking a -2.41% move from the prior day. The stock trailed the S&P 500, which registered a daily gain of 0.81%. Meanwhile, the Dow experienced a rise of 0.27%, and the technology-dominated Nasdaq saw an increase of 1.3%.
Coming into today, shares of the oil and gas exploration and production company had lost 6.15% in the past month. In that same time, the Oils-Energy sector lost 3.61%, while the S&P 500 gained 1.13%.
Investors will be eagerly watching for the performance of Occidental Petroleum in its upcoming earnings disclosure. The company's earnings report is set to be unveiled on August 5, 2026. The company is expected to report EPS of $1.94, up 397.44% from the prior-year quarter. Meanwhile, the latest consensus estimate predicts the revenue to be $7.22 billion, indicating a 11.88% increase compared to the same quarter of the previous year.
OXY's full-year Zacks Consensus Estimates are calling for earnings of $5.93 per share and revenue of $25.57 billion. These results would represent year-over-year changes of +168.33% and +0.5%, respectively.
Investors should also take note of any recent adjustments to analyst estimates for Occidental Petroleum. Recent revisions tend to reflect the latest near-term business trends. Hence, positive alterations in estimates signify analyst optimism regarding the business and profitability.
Research indicates that these estimate revisions are directly correlated with near-term share price momentum. To utilize this, we have created the Zacks Rank, a proprietary model that integrates these estimate changes and provides a functional rating system.
The Zacks Rank system, running from #1 (Strong Buy) to #5 (Strong Sell), holds an admirable track record of superior performance, independently audited, with #1 stocks contributing an average annual return of +25% since 1988. Over the last 30 days, the Zacks Consensus EPS estimate has moved 2.48% higher. Occidental Petroleum presently features a Zacks Rank of #3 (Hold).
Digging into valuation, Occidental Petroleum currently has a Forward P/E ratio of 9.04. This signifies a discount in comparison to the average Forward P/E of 19.87 for its industry.
The Oil and Gas - Integrated - United States industry is part of the Oils-Energy sector. This industry, currently bearing a Zacks Industry Rank of 174, finds itself in the bottom 30% echelons of all 250+ industries.
The Zacks Industry Rank is ordered from best to worst in terms of the average Zacks Rank of the individual companies within each of these sectors. Our research shows that the top 50% rated industries outperform the bottom half by a factor of 2 to 1.
To follow OXY in the coming trading sessions, be sure to utilize Zacks.com.
APA (APA - Free Report) closed the most recent trading day at $33.29, moving -5.05% from the previous trading session. This move lagged the S&P 500's daily gain of 0.81%. Elsewhere, the Dow saw an upswing of 0.27%, while the tech-heavy Nasdaq appreciated by 1.3%.
The oil and natural gas producer's stock has dropped by 7.74% in the past month, falling short of the Oils-Energy sector's loss of 3.61% and the S&P 500's gain of 1.13%.
The upcoming earnings release of APA will be of great interest to investors. The company's earnings report is expected on August 5, 2026. The company is expected to report EPS of $1.83, up 110.34% from the prior-year quarter. Meanwhile, our latest consensus estimate is calling for revenue of $2.5 billion, down 4.36% from the prior-year quarter.
Looking at the full year, the Zacks Consensus Estimates suggest analysts are expecting earnings of $5.29 per share and revenue of $9.09 billion. These totals would mark changes of +40.32% and -1.37%, respectively, from last year.
Investors should also take note of any recent adjustments to analyst estimates for APA. These revisions help to show the ever-changing nature of near-term business trends. With this in mind, we can consider positive estimate revisions a sign of optimism about the business outlook.
Research indicates that these estimate revisions are directly correlated with near-term share price momentum. To take advantage of this, we've established the Zacks Rank, an exclusive model that considers these estimated changes and delivers an operational rating system.
The Zacks Rank system, running from #1 (Strong Buy) to #5 (Strong Sell), holds an admirable track record of superior performance, independently audited, with #1 stocks contributing an average annual return of +25% since 1988. The Zacks Consensus EPS estimate has moved 3.86% lower within the past month. APA currently has a Zacks Rank of #3 (Hold).
In terms of valuation, APA is presently being traded at a Forward P/E ratio of 6.63. This indicates a discount in contrast to its industry's Forward P/E of 9.61.
The Oil and Gas - Exploration and Production - United States industry is part of the Oils-Energy sector. Currently, this industry holds a Zacks Industry Rank of 177, positioning it in the bottom 29% of all 250+ industries.
The Zacks Industry Rank is ordered from best to worst in terms of the average Zacks Rank of the individual companies within each of these sectors. Our research shows that the top 50% rated industries outperform the bottom half by a factor of 2 to 1.
Make sure to utilize Zacks.com to follow all of these stock-moving metrics, and more, in the coming trading sessions.
In the latest close session, CVS Health (CVS - Free Report) was down 1.59% at $102.81. This change lagged the S&P 500's daily gain of 0.81%. Elsewhere, the Dow gained 0.27%, while the tech-heavy Nasdaq added 1.3%.
The drugstore chain and pharmacy benefits manager's stock has climbed by 6.58% in the past month, falling short of the Medical sector's gain of 7% and outpacing the S&P 500's gain of 1.13%.
Analysts and investors alike will be keeping a close eye on the performance of CVS Health in its upcoming earnings disclosure. The company's earnings report is set to go public on August 5, 2026. The company's upcoming EPS is projected at $1.86, signifying a 2.76% increase compared to the same quarter of the previous year. At the same time, our most recent consensus estimate is projecting a revenue of $100.18 billion, reflecting a 1.28% rise from the equivalent quarter last year.
For the full year, the Zacks Consensus Estimates are projecting earnings of $7.44 per share and revenue of $409 billion, which would represent changes of +10.22% and +1.72%, respectively, from the prior year.
Investors should also take note of any recent adjustments to analyst estimates for CVS Health. Recent revisions tend to reflect the latest near-term business trends. As such, positive estimate revisions reflect analyst optimism about the business and profitability.
Research indicates that these estimate revisions are directly correlated with near-term share price momentum. To capitalize on this, we've crafted the Zacks Rank, a unique model that incorporates these estimate changes and offers a practical rating system.
The Zacks Rank system ranges from #1 (Strong Buy) to #5 (Strong Sell). It has a remarkable, outside-audited track record of success, with #1 stocks delivering an average annual return of +25% since 1988. Within the past 30 days, our consensus EPS projection remained stagnant. Currently, CVS Health is carrying a Zacks Rank of #2 (Buy).
With respect to valuation, CVS Health is currently being traded at a Forward P/E ratio of 14.05. This valuation marks a discount compared to its industry average Forward P/E of 15.57.
We can also see that CVS currently has a PEG ratio of 1.02. The PEG ratio is similar to the widely-used P/E ratio, but this metric also takes the company's expected earnings growth rate into account. The average PEG ratio for the Medical Services industry stood at 1.46 at the close of the market yesterday.
The Medical Services industry is part of the Medical sector. This industry currently has a Zacks Industry Rank of 96, which puts it in the top 40% of all 250+ industries.
The strength of our individual industry groups is measured by the Zacks Industry Rank, which is calculated based on the average Zacks Rank of the individual stocks within these groups. Our research shows that the top 50% rated industries outperform the bottom half by a factor of 2 to 1.
Make sure to utilize Zacks.com to follow all of these stock-moving metrics, and more, in the coming trading sessions.
Na společnost Hub Group byla podána hromadná žaloba kvůli údajným účetním chybám; firma uvedla, že její výkazy za první tři čtvrtletí roku 2025 a výroční zprávy za roky 2023 a 2024 jsou nespolehlivé.
, /PRNewswire/ -- Pomerantz LLP announces that a class action lawsuit has been filed against Hub Group, Inc. ("Hub Group" or the "Company") (NASDAQ: HUBG). Such investors are advised to contact Danielle Peyton at [email protected] or 646-581-9980, (or 888.4-POMLAW), toll-free, Ext. 7980. Those who inquire by e-mail are encouraged to include their mailing address, telephone number, and the number of shares purchased.
The class action concerns whether Hub Group and certain of its officers and/or directors have engaged in securities fraud or other unlawful business practices.
You have until August 28, 2026, to ask the Court to appoint you as Lead Plaintiff for the class if you purchased or otherwise acquired Hub Group securities during the Class Period. A copy of the Complaint can be obtained at www.pomerantzlaw.com.
[Click here for information about joining the class action]
On February 5, 2026, Hub Group announced that the Company's financial statements for the first three quarters of 2025 should not be relied upon due to "an error that resulted in the understatement of purchased transportation costs and accounts payable in the first nine months of 2025." The Company revealed that its reports for those quarters "were in each case materially misstated due to the aforementioned error and should no longer be relied upon" and that "the Company [wa]s also continuing to assess the effectiveness of its disclosure controls and procedures and internal control over financial reporting and appropriate remediation steps." The Company also estimated that "[t]he total amount of the reduction to accounts payable and purchased transportation costs related to this issue that was recorded during these periods is $77 million." As such, Hub Group stated that it "plans to restate its financial statements for the first, second and third quarters of 2025."
On this news, Hub Group's stock price fell $9.37 per share, or 18.25%, to close at $41.96 per share on February 6, 2026.
Then, on May 12, 2026, Hub Group announced that it had "identified certain transactions that were prematurely or incorrectly recognized or not adequately supported," causing its 2023 and 2024 annual reports filed with the SEC to be "materially misstated," such that they "should no longer be relied upon." The Company did not quantify the expected misstatement, although it "expect[ed] to conclude that it did not maintain effective disclosure controls and procedures and internal control over financial reporting for each of the years ended December 31, 2024 and 2023."
On this news, Hub Group's stock price fell $5.24 per share, or 12.52%, to close at $36.62 per share on May 12, 2026.
Pomerantz LLP, with offices in New York, Chicago, Los Angeles, London, Paris, and Tel Aviv, is acknowledged as one of the premier firms in the areas of corporate, securities, and antitrust class litigation. Founded by the late Abraham L. Pomerantz, known as the dean of the class action bar, Pomerantz pioneered the field of securities class actions. Today, more than 85 years later, Pomerantz continues in the tradition he established, fighting for the rights of the victims of securities fraud, breaches of fiduciary duty, and corporate misconduct. The Firm has recovered numerous multimillion-dollar damages awards on behalf of class members. See www.pomlaw.com.
Attorney advertising. Prior results do not guarantee similar outcomes.
International Paper dočasně zastavila provoz v závodě Pine Hill v Alabamě kvůli poškození střechy způsobenému počasím. Obnovení výroby očekává v srpnu.
, /PRNewswire/ -- International Paper (NYSE: IP; LSE: IPC) proactively decided to temporarily suspend operations at its Pine Hill, Ala., mill after a weather event damaged a critical roof at the facility. International Paper values the safety of its employees and contractors above all else and took this action out of an abundance of caution.
The company is assessing required repairs and currently expects to resume manufacturing in August. The company is also working closely with customers to manage any potential impacts and appreciates the support of its employees, customers and stakeholders while working through this process safely.
About International Paper (NYSE: IP; LSE: IPC)
International Paper creates sustainable packaging solutions that enable our customers, teammates and shareowners to thrive in an ever-changing world. We are a leader in corrugated packaging, partnering with customers across industries to protect what matters most, strengthen supply chains and create lasting value. Learn more at internationalpaper.com.
Forward-Looking Statements
This news release includes forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995, as amended. Forward-looking statements can be identified by the use of forward-looking or conditional words such as "expects," "anticipates," "believes," "estimates," "could," "should," "can," "may," "will," "remain," "confident," "commit" and "plan" or similar expressions. All statements in this news release regarding the temporary closure of our Pine Hill, Alabama mill due to severe weather, including our expected timeline for resuming operations, potential impact, if any, to our ability to service customers or potential impact, if any, to our financial results and operations are forward-looking statements.
These forward-looking statements reflect management's current views and are subject to risks and uncertainties that could cause actual results and the timing of events to differ materially from those expressed or implied in these forward-looking statements. Forward-looking statements should, therefore, be construed in light of such risk factors as described in our Annual Report on Form 10-K for the year ended December 31, 2025 as filed with the U.S. Securities and Exchange Commission on February 27, 2026.
Cohen & Steers oznámila předběžná aktiva pod správou ve výši 100,1 miliardy USD k 30. červnu 2026, což je nárůst z 99,5 miliardy USD na konci května. Růst podpořily čisté přílivy ve výši 495 milionů USD a zhodnocení trhu ve výši 611 milionů USD, částečně kompenzované distribucemi ve výši 462 milionů USD.
Resources Investor Relations Journalists Agencies Client Login Send a Release News Products Contact , /PRNewswire/ -- Cohen & Steers, Inc. (NYSE: CNS) today reported preliminary assets under management of $100.1 billion as of June 30, 2026, an increase of $644 million from assets under management of $99.5 billion at May 31, 2026. The increase was due to market appreciation of $611 million and net inflows of $495 million, partially offset by distributions of $462 million.
Assets Under Management
(unaudited)
($ in millions)
AUM
Net
Market
AUM
By investment vehicle:
5/31/2026
Flows
App/(Dep)
Distributions
6/30/2026
Institutional Accounts:
Advisory
$22,698
$36
$171
-
$22,905
Subadvisory
15,712
(236)
194
(52)
15,618
Total Institutional Accounts
38,410
(200)
365
(52)
38,523
Open-end Funds
48,456
695
196
(354)
48,993
Closed-end Funds
12,589
-
50
(56)
12,583
Total AUM
$99,455
$495
$611
($462)
$100,099
About Cohen & Steers. Cohen & Steers is a leading global investment manager specializing in real assets and alternative income, including listed and private real estate, preferred securities, infrastructure, resource equities, commodities, as well as multi-strategy solutions. Founded in 1986, the firm is headquartered in New York City, with offices in London, Dublin, Hong Kong, Tokyo and Singapore.
Resources Investor Relations Journalists Agencies Client Login Send a Release News Products Contact , /PRNewswire/ -- Labcorp Holdings Inc. (NYSE: LH), a global leader of innovative and comprehensive laboratory services, announced today that its Board of Directors has declared a cash dividend of $0.72 per share of common stock. The dividend will be payable on September 11, 2026, to stockholders of record as of the close of business on August 28, 2026.
About Labcorp
Labcorp (NYSE: LH) is a global leader of innovative and comprehensive laboratory services that helps doctors, hospitals, pharmaceutical companies, researchers, and patients make clear and confident decisions. We provide insights and advance science to improve health and improve lives through our unparalleled diagnostics and drug development laboratory capabilities. The company's nearly 71,000 employees serve clients in approximately 100 countries, provided support for more than 85% of the new drugs and therapeutic products approved by the FDA in 2025, and performed more than 750 million tests for patients around the world. Learn more at www.labcorp.com.
Sempra oznámila změny ve vedení po plánovaném prodeji 45% podílu v Sempra Infrastructure Partners společnosti KKR. Karen Sedgwicková se stane generální ředitelkou a prezidentkou SoCalGas, Justin Bird se stane výkonným viceprezidentem a finančním ředitelem Sempra.
, /PRNewswire/ -- Sempra (NYSE: SRE) today announced leadership appointments that mark another strategic milestone in advancing the company's mission to build America's leading utility growth business while bolstering leadership continuity and talent development.
The appointments follow the company's September 2025 announcement of its agreement to sell a 45% equity interest in Sempra Infrastructure Partners (Sempra Infrastructure), one of North America's leading energy infrastructure platforms, to affiliates of KKR. The company continues to expect the transaction to close in the third quarter of 2026, and Bob Patel was recently announced as the incoming chief executive officer of Sempra Infrastructure, effective upon close.
Advancing Utility Growth Strategy with New Leadership Appointments
With the closing of the referenced transaction, Karen Sedgwick, currently executive vice president and chief financial officer of Sempra, will become chief executive officer and president of the Southern California Gas Company (SoCalGas), bringing over 30 years of experience at the Sempra family of companies, including an established leadership background in utility practice and procedure, external and regulatory affairs, operations and safety, to lead the nation's largest gas distribution utility. In addition, she will continue to serve on the board of directors of SoCalGas.
Concurrently, Justin Bird, executive vice president of Sempra and chief executive officer of Sempra Infrastructure, will become executive vice president and chief financial officer of Sempra. Combined with his track record of value creation in the capital markets at the helm of Sempra Infrastructure, Bird has a strong, multi-disciplinary foundation for a successful transition into the CFO role. With more than 20 years of experience at Sempra, Bird has held leadership roles in treasury, financial planning, corporate development and legal, including five years of prior experience in commercial and project finance. In addition to his current oversight of Sempra's corporate development program, Bird will also lead the company's investor relations, treasury, financial planning, audit, insurance and tax functions. He will continue to serve on the boards of directors of Sempra Infrastructure and Oncor Electric Delivery Company LLC.
The referenced leadership changes will become effective on or around the closing of the transaction, expected in the third quarter of 2026, subject to necessary regulatory and other approvals and closing conditions.
"This is an exciting time for our company as we continue to advance the growth of our utility businesses. These appointments further our mission alignment and strengthen our ability to deliver long-term value for our stakeholders," said Jeffrey W. Martin, chairman and chief executive officer of Sempra. "Our board has great confidence in both Karen and Justin and the leadership they will bring to their new roles. Karen is a proven leader who has touched all aspects of our California utilities over the last three decades and I am excited to see her take on the role of leading America's largest natural gas distribution utility. I am also excited to partner with Justin as he broadens the scope of his financial and strategic responsibilities and extends his positive impact across the enterprise."
Sempra's focus on developing and rotating leaders at all levels of the company has helped cultivate a mission-driven culture centered on the recognition that human capital is the most important corporate resource, as demonstrated by its recent inclusion on The Wall Street Journal's inaugural "Best Companies for the Future" list, where the company ranked among the top companies in America for leadership and talent readiness.
Strengthening Financial Position and Funding Growth
The pending transaction plays a central role in advancing Sempra's strategic priorities by generating substantial cash proceeds and supporting disciplined capital allocation to concentrate the company's investment strategy in regulated U.S. utility operations in Texas and California. Before adjustments, the $10 billion transaction announced in September 2025 implies an equity value of approximately $22.2 billion for Sempra Infrastructure.1
Upon closing, affiliates of KKR will hold a 65% equity stake in Sempra Infrastructure, while Sempra will retain a 25% interest alongside an affiliate of Abu Dhabi Investment Authority's existing 10% stake. The impact of the transaction, together with other elements of the company's simplified business strategy, are expected to result in approximately 95% of Sempra's earnings coming from regulated U.S. utilities in 2027, while also supporting the company's goal of having more than 60% of its rate base located in Texas through the end of the decade.2 These impacts also are expected to eliminate the need for common equity issuances in the company's 2026-2030 base capital plan3 and support execution of the company's 2026 value creation initiatives, including efficiently sourcing capital for growth and deconsolidating Sempra Infrastructure's debt from Sempra's consolidated financials.
About Sempra
Sempra's mission is to build America's leading utility growth business. As owner of one of the largest energy networks on the continent, Sempra is electrifying and improving energy resilience in California and Texas, the two largest economies in the U.S. The company is recognized as a leader in responsible business practices and for its high-performance culture focused on safety and operational excellence, as demonstrated by Sempra's inclusion in The Wall Street Journal's Management Top 250 and Fortune's World's Most Admired Companies. More information about Sempra is available at sempra.com and on social media @sempra.
This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Forward-looking statements are based on assumptions about the future, involve risks and uncertainties, and are not guarantees. Future results may differ materially from those expressed or implied in any forward-looking statement. These forward-looking statements represent our estimates and assumptions only as of the date of this press release. We assume no obligation to update or revise any forward-looking statement as a result of new information, future events or otherwise.
In this press release, forward-looking statements can be identified by words such as "believe," "expect," "intend," "anticipate," "contemplate," "plan," "estimate," "project," "forecast," "envision," "should," "could," "would," "will," "confident," "may," "can," "potential," "possible," "proposed," "in process," "construct," "develop," "opportunity," "preliminary," "pro forma," "strategic," "initiative," "target," "outlook," "optimistic," "poised," "positioned," "maintain," "continue," "progress," "advance," "goal," "aim," "commit," or similar expressions, or when we discuss our guidance, priorities, strategies, goals, vision, mission, projections, intentions or expectations.
Factors, among others, that could cause actual results and events to differ materially from those expressed or implied in any forward-looking statement include: California wildfires, including potential liability for damages regardless of fault and any inability to recover all or a substantial portion of costs from insurance, the wildfire fund established by California Assembly Bill 1054 and the wildfire fund continuation account established by California Senate Bill 254, rates from customers or a combination thereof; decisions, disallowances or denials of cost recovery, audits, investigations, inquiries, ordered studies, regulations, legislative actions, denials or revocations of permits, consents, approvals or other authorizations, renewals of franchises, and other actions, including the failure to honor contracts and commitments, by the (i) Comisión Nacional de Energía, California Public Utilities Commission (CPUC), U.S. Department of Energy, U.S. Federal Energy Regulatory Commission, U.S. Internal Revenue Service, Public Utility Commission of Texas and other regulatory bodies and (ii) U.S., Mexico and states, counties, cities and other jurisdictions therein and in other countries where we do business; the success of business development efforts, construction projects, acquisitions, divestitures, and other significant transactions such as the planned sale of a portion of our equity interest in Sempra Infrastructure Partners, including risks related to, as applicable, (i) being able to reach a positive final investment decision, (ii) negotiating pricing and other terms in definitive contracts, (iii) completing construction projects or other transactions on schedule and budget, (iv) realizing anticipated benefits from any of these efforts if completed, (v) obtaining regulatory and other approvals and (vi) third parties honoring their contracts and commitments, including with respect to closing or post-closing payments; changes to our capital expenditure plans and their potential impact on rate base or other growth; changes, due to evolving economic, political and other factors and increasing geopolitical instability as a result of wars or other conflicts in various parts of the world, to (i) trade and other foreign policy, including the imposition of tariffs by the U.S. and foreign countries (and uncertainty related to the implementation and enforceability thereof), and (ii) laws and regulations, including those related to tax and the energy industry in the U.S. and Mexico; litigation, arbitration, property disputes and other proceedings; cybersecurity threats, including by nation-state actors, of ransomware or other attacks on our systems, the energy grid or our other infrastructure, or the systems of third parties with which we conduct business; the availability, uses, sufficiency, and cost of capital resources and our ability to borrow money or otherwise raise capital on favorable terms and meet our obligations, which can be affected by, among other things, (i) actions by credit rating agencies to downgrade our credit ratings or place those ratings on negative outlook, (ii) instability in the capital markets, and (iii) fluctuating interest rates and inflation; the impact of efforts to increase affordability of U.S. utility customer rates on our ability to obtain cost recovery from applicable regulators, our capital expenditure and other growth plans and our ability to advance statewide policies; the impact on affordability of customer rates, cost of capital and operating margin due to (i) volatility in inflation, interest rates, commodity prices, tariff rates, and foreign currency exchange rates and (ii) with respect to San Diego Gas & Electric Company's (SDG&E) and Southern California Gas Company's (SoCalGas) businesses, the cost of meeting the demand for lower carbon and reliable energy in California; the impact of climate policies, laws, rules, regulations, trends and required disclosures, including actions to reduce or eliminate reliance on natural gas, increased uncertainty in the political or regulatory environment for California natural gas distribution companies, the risk of nonrecovery for stranded assets, and uncertainty related to emerging technologies; weather, natural disasters, pandemics, accidents, equipment failures, explosions, terrorism, information system outages or other events, such as work stoppages, that disrupt our operations, damage our facilities or systems, cause the release of harmful materials or fires or subject us to liability for damages, fines and penalties, some of which may not be recoverable through regulatory mechanisms or insurance or may impact our ability to obtain satisfactory levels of affordable insurance; the availability of electric power, natural gas and natural gas storage and transportation capacity, including disruptions caused by failures in the transmission grid or pipeline and storage systems or limitations on the injection and withdrawal of natural gas from storage facilities; Oncor Electric Delivery Company LLC's (Oncor) ability to reduce or eliminate its quarterly dividends due to regulatory and governance requirements and commitments, including by actions of Oncor's independent directors or a minority member director; and other uncertainties, some of which are difficult to predict and beyond our control.
These risks and uncertainties are further discussed in the reports that Sempra has filed with the U.S. Securities and Exchange Commission (SEC). These reports are available through the EDGAR system free-of-charge on the SEC's website, www.sec.gov, and on Sempra's website, www.sempra.com. Investors should not rely unduly on any forward-looking statements.
Sempra Infrastructure Partners and its subsidiaries, and the Sempra Texas utilities (Oncor and Sharyland Utilities) are not the same companies as the Sempra California utilities, SDG&E or SoCalGas, nor are they regulated by the California Public Utilities Commission (CPUC).
1 Implied valuation is based on proceeds before KKR fee reimbursement of $338M, development credits of $340M and other closing and post-closing adjustments.
2 Reflects Sempra's proportionate share of its utilities' combined projected 2030 rate base, based on Sempra's ownership interest in each utility.
3 Capital plan assumes $0.6B of shares issued via direct stock purchase plan (DRIP) and 401(k) plans, which is a projection based on historical issuances under these plans. Capital plan also assumes share issuances under existing forward contracts in Sempra's at-the-market offering program that are expected to settle within the plan period.
Arthur J. Gallagher & Co. prostřednictvím RPS koupila Med James, Inc., velkoobchodního pojišťovacího makléře z Overland Parku. Podmínky transakce nebyly zveřejněny.
, /PRNewswire/ -- Arthur J. Gallagher & Co. today announced that its U.S. wholesale brokerage, binding authority and programs division, Risk Placement Services, Inc. (RPS), has acquired Overland Park, Kansas-based Med James, Inc. Terms of the transaction were not disclosed.
Med James is a managing general agency (MGA) and wholesale insurance broker serving retail agents. Pam Donahue and the Med James team will remain in their current location under the direction of Jacey Norberg, VP-North Central Region for RPS.
"Med James has a strong reputation in the wholesale space and expands RPS's capabilities in the region," said J. Patrick Gallagher, Jr., Chairman and CEO. "I am very pleased to welcome the Med James team to our growing, global family of professionals."
Arthur J. Gallagher & Co. (NYSE:AJG), a global insurance brokerage, risk management and consulting services firm, is headquartered in Rolling Meadows, Illinois. Gallagher provides these services in approximately 130 countries around the world through its owned operations and a network of correspondent brokers and consultants.
Remitly získala od centrální banky SAE licenci SVF s Exchange Business Category IV, což jí umožní rozšířit nabídku nových produktů pro zákazníky v SAE.
ABU DHABI, July 09, 2026 (GLOBE NEWSWIRE) -- Remitly Global, Inc. (NASDAQ: RELY) is among the first international remittance companies to secure a Stored Value Facilities (SVF) license with Exchange Business Category IV from the Central Bank of the UAE, a major milestone in one of the world's largest remittance markets. This authorization further extends Remitly’s regulated global footprint and our service to customers across more than 175 countries, strengthening our position for long term growth in the region. The license follows a rigorous review process with the CBUAE and reflects the formal recognition of Remitly's commitment to the UAE and its customers. With the license secured, Remitly will be able to bring new products, purpose-built to serve UAE customers.
The UAE moves an estimated $50 billion across borders every year. Currently people in the UAE can transfer money via Remitly across more than 175 countries, with upfront fees and exchange rates, high transfer limits, and the speed and reliability that has earned the trust of 9.6 million quarterly users worldwide, who moved over $80 billion in send volume over the last twelve months. With CBUAE authorization in place, Remitly can now build and introduce new products designed to strengthen customers' financial lives across countries.
"The UAE is one of the most important remittance regions in the world, and receiving our CBUAE license is a defining moment for Remitly”, said Davis Dominic Parakal, UAE CEO at Remitly. “We are grateful for the rigorous engagement with CBUAE throughout this process and are proud to operate to the high bar it has set for the industry. We are here to build something valuable for the diverse communities across the UAE."
This authorization arrives as the UAE accelerates its position as a global fintech leader. The CBUAE's dedicated digital remittance license category is designed specifically for globally minded operators committed to investing in the region for the long term. Remitly's presence here directly supports the UAE's 'We the UAE 2031' vision, which places fintech and digital financial services at the heart of the country's ambition to double the contribution of its digital economy to GDP.
The UAE license is the latest chapter in Remitly's global drive to expand access to fast, fair, and transparent financial services for the millions of people worldwide who have historically been underserved.
About Remitly: Remitly is a trusted provider of financial services that transcend borders. With a footprint spanning more than 175 countries, Remitly has built one of the world’s leading global money movement platforms, trusted by millions of customers. Remitly continues to evolve beyond a remittance company into a diversified, cross-border financial services provider, serving both consumers and businesses across a growing set of use cases.
KB Home vyhlásila čtvrtletní hotovostní dividendu 0,25 USD na akcii. Vyplacena bude 20. srpna 2026 akcionářům, kteří budou držet akcie k 6. srpnu 2026.
Resources Investor Relations Journalists Agencies Client Login Send a Release News Products Contact , /PRNewswire/ -- The board of directors of KB Home (NYSE: KBH) has declared a quarterly cash dividend of $.25 per share on the Company's common stock, payable on August 20, 2026 to stockholders of record on August 6, 2026.
About KB Home
KB Home is one of the largest and most trusted homebuilders in the U.S. We operate in 50 markets, have built over 700,000 quality homes in our nearly 70-year history, and are honored to be one of the top customer-ranked national homebuilders based on third-party buyer surveys. What sets KB Home apart is building strong, personal relationships with every customer and creating an exceptional experience that offers our homebuyers the ability to personalize their home based on what they value at a price they can afford. As the industry leader in sustainability, KB Home has achieved one of the highest residential energy-efficiency ratings and delivered more ENERGY STAR® certified homes than any other builder, helping to lower the total cost of homeownership. For more information, visit kbhome.com.
For Further Information:
Jill Peters, Investor Relations Contact
(310) 893-7456 or
[email protected]
IRVING, Texas--(BUSINESS WIRE)--Darling Ingredients Inc. (NYSE: DAR) announced today that it will host a conference call on Thursday, July 30, 2026, at 9 a.m. Eastern Time (8 a.m. Central Time) to discuss second quarter 2026 financial results, which will be released earlier that day, and provide an update on company operations. A presentation with accompanying supplemental financial data will also be available at darlingii.com/investors.
To access the call as a listener, please register for the audio-only webcast.
To join the call as a participant to ask a question, please register in advance to receive a confirmation email with the dial-in number and PIN for immediate access on July 30 or call 833-461-5787 (United States) or 626-884-3620 (international) using access code 745365725.
A replay of the call will be available online via the webcast registration link two hours after the call ends. A transcript will be posted at darlingii.com/investors within 24 hours.
About Darling Ingredients
A pioneer in circularity, Darling Ingredients Inc. (NYSE: DAR) takes material from the animal agriculture and food industries, and transforms them into valuable ingredients that nourish people, feed animals and crops, and fuel the world with renewable energy. The company operates over 260 facilities in more than 15 countries and processes about 15% of the world’s animal agricultural by-products, produces about 30% of the world’s collagen (both gelatin and hydrolyzed collagen), and is one of the largest producers of renewable energy. To learn more, visit darlingii.com. Follow us on LinkedIn.
SoFi Technologies oznámila akvizici investičního AI nástroje Composer, který umí podle zadání vytvářet a automaticky provádět obchodní strategie. Trh na zprávu reagoval pozitivně.
The stock of SoFi Technologies (SOFI +5.02%) has been a huge disappointment for investors recently; it's down 32% year to date as of this writing.
However, it's been performing well and building its business, putting it in a position to climb again. Management just announced its latest acquisition, the artificial intelligence (AI) investing tool Composer. Is this its next big catalyst?
The one-stop financial app SoFi aims to be a one-stop financial app for its users. It started out as a lender and has expanded into a large array of financial services, including investing tools.
These other services do many positive things for SoFi. They open up new sources of revenue; hedge the business against high interest rates, which can hurt lenders; and generate high cross-selling opportunities, which are part of management's long-term growth strategy. The platform also offers several AI-based tools that help customers get their money right and feed into the overall model.
Image source: Getty Images.
For example, customers with a bank account might use its AI features to analyze their finances, and the bank's AI could detect a better SoFi credit card. The users might then switch to that credit card, giving them two of the company's products.
Management targets young professionals, an upwardly mobile population that likes all things digital and AI. Composer is an AI agent that can create and execute investing strategies using natural language. Investors can create their own custom plan or use community-built strategies, and they can automate the execution of stock trades based on prompts and criteria. Composer isn't the only AI investing agent, but it fits into SoFi's broader model and offers greater value for its members.
Can the stock recover? SoFi has launched a slew of tech-first services this year, including its own stablecoin and blockchain-based international wire transfers. These have not helped the stock recover, although the market did respond positively to the Composer announcement, and shares have started to bounce back from lows earlier this year.
Today's Change
(
5.02
%) $
0.89
Current Price
$
18.62
In most respects, SoFi is performing well. Adjusted net revenue accelerated to 41% growth year over year in the 2026 first quarter, and earnings per share increased from $0.06 to $0.13. The loan business has momentum, with a 68% year-over-year increase in originations this quarter, spread across categories.
On its own, an AI agent won't be the answer to a SoFi rebound, but it's another way the company can keep attracting record new users and set itself up for success. And there's still an opportunity to buy on the dip at the current price.
Varonis Systems oznámila, že výsledky za 2. čtvrtletí 2026 zveřejní po uzavření amerických trhů 28. července 2026. Ve stejný den uspořádá konferenční hovor v 16:30 ET.
July 09, 2026 16:05 ET | Source: Varonis Systems, Inc.
MIAMI, July 09, 2026 (GLOBE NEWSWIRE) -- Varonis Systems, Inc. (Nasdaq: VRNS), the data and AI security leader, announced that it will report its second quarter 2026 financial results following the close of the U.S. financial markets Tuesday, July 28, 2026.
In conjunction with this announcement, Varonis will host a conference call Tuesday, July 28, 2026, at 4:30 p.m. ET to discuss the company's financial results.
To access this call, dial 877-425-9470 (domestic) or 201-389-0878 (international). The conference ID number is 13761605. A replay of this conference call will be available through August 11, 2026, at 844-512-2921 (domestic) or 412-317-6671 (international). The replay passcode is 13761605.
A live webcast of this conference call will be available on the “Investor Relations” page of the company's website (https://ir.varonis.com), and the replay will be archived on the website for one year.
Additional Resources
For more information on Varonis’ solution portfolio, please visit www.varonis.com.Visit our blog, and join us on LinkedIn and YouTube. About Varonis
Varonis (Nasdaq: VRNS) secures AI and the data that powers it. The Varonis platform gives organizations automated visibility and control over their critical data wherever it lives and helps ensure safe and trustworthy AI from code to runtime. Backed by 24x7x365 managed detection and response, Varonis gives thousands of organizations worldwide the confidence to adopt AI, reduce data exposure, and stop AI-powered threats.
Investor Relations Contact:
Tim Perz
Varonis Systems, Inc.
646-640-2112 [email protected]
News Media Contact:
Rachel Hunt
Varonis Systems, Inc.
877-292-8767 (ext. 1598) [email protected]
HCC Healthcare podepsala dohodu o spojení s RF Acquisition Corp III, která má otevřít cestu k zalistování na Nasdaq. Hodnota transakce je zhruba 500 milionů USD.
Transaction expected to provide HCC Healthcare with access to public capital markets to accelerate growth in integrated medical and long-term care services across Asia July 09, 2026 17:27 ET | Source: RF Acquisition Corp III
SINGAPORE, July 09, 2026 (GLOBE NEWSWIRE) -- HCC Healthcare Pte. Ltd. (“HCC Healthcare” or the “Company”), a private company limited by shares incorporated in Singapore, today announced that it has signed a Business Combination Agreement (the “BCA”) with RF Acquisition Corp III (Nasdaq: RFAM) (“RF Acquisition”), a publicly traded special purpose acquisition company. Upon the closing of the proposed business combination, HCC Healthcare is expected to become a publicly traded company, with its securities listed on the Nasdaq Stock Market.
HCC Healthcare operates through its consolidated operating subsidiaries in Taiwan. On a pro forma basis, HCC Healthcare and its network of affiliated and allied care providers (together, the “Group”) will bring together an integrated care network of affiliated and allied hospitals, clinics, pharmacies, and long-term care institutions, to form one of the largest platforms for integrated medical and long-term care services in Taiwan. Across this network, the Group will provide medical transportation, medical consumables procurement, medical and long-term care education, and medical information and consulting services. On a pro forma combined basis, the network is expected to encompass more than 120 long-term care facilities and over 9,000 beds, including one of the largest caregiving institutions in Taiwan, with more than 1,300 beds, under a distinctive “hospital-within-an-eldercare-institution” ecosystem model. The Group also intends to advance Taiwan’s national long-term care agenda through community- and home-based services, including case management for more than 7,000 individuals, with operations concentrated in Northern Taiwan, a region representing approximately one-third of the country’s population. Following the closing of the proposed business combination, HCC Healthcare intends to use the proceeds to accelerate the consolidation and integration of the Group into a unified platform, with the goal of expanding service capacity, improving care coordination, and extending the Group's reach.
Taiwan, Japan, and many other Asian economies are undergoing a rapid demographic transformation toward super-aged societies, a shift that the Company believes is generating substantial and growing demand for coordinated, comprehensive healthcare and long-term care solutions. HCC Healthcare is well positioned to meet this demand through its “one-stop” integrated care model, which is designed to bring together medical care, long-term care, caregiver support, rehabilitation, hemodialysis, pharmaceutical, infection-control, nutritional, and social-work services within a single coordinated framework.
The Group’s strategic growth roadmap is built on four priorities: (i) deploying a proprietary AI platform that integrates spatial intelligence, causal inference, and multimodal clinical data to strengthen decision support and operational performance across the affiliated care network; (ii) expanding into the Japanese market, leveraging the Group’s existing operational infrastructure and Japan’s advanced regulatory framework for regenerative medicine; (iii) developing cross-sector partnerships with fitness and wellness operators to create integrated care pathways spanning preventive health, chronic disease management, and rehabilitation; and (iv) accelerating investment in precision and regenerative medicine, including AI-driven biomarker profiling, to pursue personalized care delivery across the region.
“Signing this agreement is an important milestone in HCC Healthcare’s journey,” said Jack Hsiao, Chief Executive Officer of HCC Healthcare. “As Asia enters a super-aged era, we believe an integrated, technology-enabled model of medical and long-term care is essential. We further believe that a Nasdaq listing would give us the platform and resources to scale that model, first in Taiwan and Japan, and ultimately across the region, while creating long-term value for patients, partners, and shareholders.”
“We are excited to partner with HCC Healthcare and support their vision for integrated medical and long-term care in Asia,” said Tse Meng Ng, Chief Executive Officer of RF Acquisition. “This business combination agreement represents what we believe is a significant step forward in bringing HCC Healthcare’s innovative care model to the public markets, and we look forward to working together to help create value for patients, communities, and our shareholders alike.”
The BCA reflects a pre-transaction equity value of HCC Healthcare of approximately US$500 million. The transaction is expected to close in the fourth quarter of 2026, subject to the approval of RF Acquisition’s shareholders, the effectiveness of the Registration Statement on Form F-4 (the “Form F-4”) to be filed with the U.S. Securities and Exchange Commission (the “SEC”), and the satisfaction of other customary closing conditions.
Bedrock Investment Private Limited is acting as strategic consultant to HCC Healthcare. EarlyBirdCapital, Inc. is acting as financial advisor to RF Acquisition. K&L Gates LLP is acting as U.S. legal counsel to HCC Healthcare, and PricewaterhouseCoopers Legal is acting as HCC Healthcare’s Taiwan legal counsel. Winston Taylor LLP is acting as U.S. legal counsel to RF Acquisition.
About HCC Healthcare
HCC Healthcare Pte. Ltd., through its consolidated operating subsidiaries in Taiwan, and on a pro forma basis giving effect to its network of affiliated and allied care providers, forms one of the largest integrated platforms for medical and long-term care services in Taiwan, spanning hospitals, clinics, pharmacies, rehabilitation, hemodialysis, caregiver support, and community- and home-based care. Through its “one-stop” integrated care model and “hospital-within-an-eldercare-institution” ecosystem, the Group encompasses, on a pro forma combined basis, more than 120 long-term care facilities and over 9,000 beds, and is pursuing growth in AI-enabled care, the Japanese market, wellness partnerships, and precision and regenerative medicine. For more information, visit www.hcchealthcaregroup.com.
Note Regarding Certain Operational Information
Certain operational information in this press release, including the number of long-term care facilities, beds, and individuals under case management, is presented on a combined or pro forma basis giving effect to the Group’s affiliated and allied care network, which includes providers that are not wholly owned or consolidated subsidiaries of HCC Healthcare. Such information is unaudited, is presented for illustrative purposes only, and does not purport to represent the actual consolidated operations or financial position of HCC Healthcare as of any date or for any period. The Company’s plans to consolidate or integrate additional operations within this network are subject to a number of conditions and approvals and may not be completed as described or at all.
Forward-Looking Statements
This press release contains certain “forward-looking statements” within the meaning of the Securities Act of 1933, as amended, and section 21E of the Securities Exchange Act of 1934, as amended, including statements regarding the proposed business combination and related transactions, the expected timing and benefits of the transaction, anticipated valuation, the presentation of pro forma and combined operational information, the Company’s plans to consolidate or integrate operations within its affiliated care network, and the Group’s strategy, market opportunity, and future operations and performance. Forward-looking statements may be identified by words such as “believe,” “expect,” “anticipate,” “intend,” “plan,” “estimate,” “pro forma,” “will,” “may,” “would,” “intends to,” “is designed to,” and similar expressions. You should not place undue reliance on these forward-looking statements. These statements are based on current expectations and assumptions as of the date of this press release and are subject to known and unknown risks and uncertainties, and other factors, many of which are beyond the control of HCC Healthcare and RF Acquisition, that could cause actual results to differ materially, including, among others: the risk that the transaction may not be completed on the anticipated timeline or at all; the failure to obtain required shareholder approvals or to satisfy other closing conditions; the amount of redemptions by RF Acquisition’s public shareholders; the effectiveness of the Form F-4; changes in applicable laws or regulations in Taiwan, Japan, Singapore, or the United States; the Company’s ability to consolidate or integrate operations within its affiliated care network; the Group’s ability to execute its growth strategy and integrate new businesses; risks associated with AI technology development and deployment, including the ability to develop, implement, and scale proprietary AI platforms; regulatory risks in Taiwan, Japan and other jurisdictions related to regenerative medicine and healthcare services; risks related to partnership strategies, including the ability to identify, negotiate, and maintain strategic partnerships; competitive and scientific risks in precision and regenerative medicine, including rapid technological change and evolving industry standards; geopolitical risks, including risks arising from regional political instability or cross-strait tensions that may adversely affect the Company's operations in Taiwan or its planned expansion into other Asian markets; risks related to currency exchange rate fluctuations, including with respect to the New Taiwan Dollar, the Japanese Yen, and other currencies, relative to the U.S. Dollar, which may affect the Company's results of operations and financial condition; risks associated with integrating fragmented or affiliated care provider networks, including the ability to achieve anticipated operational and financial synergies; and other risks to be detailed in the Form F-4 and other filings with the SEC. Neither HCC Healthcare nor RF Acquisition undertakes any obligation to update any forward-looking statement, except as required by law.
Additional Information and Where to Find It
In connection with the proposed transaction, the Form F-4 (which will include a preliminary proxy statement/prospectus of RF Acquisition) is expected to be filed with the SEC. After the Form F-4 is declared effective, a definitive proxy statement/prospectus will be mailed to RF Acquisition’s shareholders as of the record date established for voting on the proposed transaction. INVESTORS AND SECURITY HOLDERS ARE URGED TO READ THE FORM F-4, THE PROXY STATEMENT/PROSPECTUS, AND ALL OTHER RELEVANT DOCUMENTS FILED OR TO BE FILED WITH THE SEC, AS WELL AS ANY AMENDMENTS AND SUPPLEMENTS THERETO, CAREFULLY AND IN THEIR ENTIRETY WHEN THEY BECOME AVAILABLE BECAUSE THEY WILL CONTAIN IMPORTANT INFORMATION ABOUT HCC HEALTHCARE, RF ACQUISITION, AND THE PROPOSED TRANSACTION. The Form F-4, including the proxy statement/prospectus, and other relevant documents (when they become available) may be obtained free of charge at the SEC’s website at www.sec.gov. In addition, investors and security holders may obtain copies of the documents filed with the SEC, free of charge, by directing a request to: RF Acquisition Corp III, 1345 Avenue of the Americas, 33rd Floor, New York, NY 10105, Attention: Investor Relations, or by email at [email protected], or to: HCC Healthcare Pte. Ltd., at the contact information set forth below.
Participants in the Solicitation
HCC Healthcare, RF Acquisition, and their respective directors and executive officers may be deemed participants in the solicitation of proxies in connection with the proposed transaction. Information regarding such participants and their interests in the proposed transaction will be set forth in the Form F-4, including the proxy statement/prospectus, when filed with the SEC. Additional information regarding the directors and executive officers of RF Acquisition is contained in RF Acquisition’s Registration Statement on Form S-1, as amended (Registration No. 333-290947), which was filed with the SEC. Additional information regarding HCC Healthcare and its directors and executive officers will be included in the Form F-4 when it is filed with the SEC. These documents are (or will be) available free of charge at the SEC’s website at www.sec.gov or by directing a request to the contact information set forth above.
No Offer or Solicitation
This press release is for informational purposes only and does not constitute an offer to sell or buy, or the solicitation of an offer to sell or buy, any securities, nor shall there be any sale of securities in any jurisdiction in which such offer, solicitation, or sale would be unlawful prior to registration or qualification under the securities laws of any such jurisdiction.
Sabra Health Care REIT se rychle přesouvá do modelu SHOP, aby těžila z demografického trendu stárnutí populace. AFFO za 1. čtvrtletí dosáhlo 0,39 USD na akcii.
SummarySabra Health Care REIT remains a Buy, driven by its aggressive pivot into the Seniors Housing Operating Portfolio model.SBRA's SHOP transition offers direct exposure to demographic tailwinds from the 'Silver Tsunami,' positioning for significant potential occupancy and AFFO growth.Q1 results were strong, with AFFO at $0.39/share, nearly reaching the annual investment target, and a 77% dividend payout ratio supporting a ~6% yield.Despite near-term macro headwinds and increased operational risk, SBRA's intrinsic value estimate of $23.41/share implies re-rating potential above current levels. Drazen Zigic/iStock via Getty Images
Introduction The last time I covered Sabra Health Care REIT, Inc. (SBRA), I reiterated its Buy rating, highlighting how the company was rapidly pivoting into SHOP (Seniors Housing Operating Portfolio) in order to better position
3.2K Followers
Analyst’s Disclosure: I/we have no stock, option or similar derivative position in any of the companies mentioned, but may initiate a beneficial Long position through a purchase of the stock, or the purchase of call options or similar derivatives in SBRA over the next 72 hours. I wrote this article myself, and it expresses my own opinions. I am not receiving compensation for it (other than from Seeking Alpha). I have no business relationship with any company whose stock is mentioned in this article.
Seeking Alpha's Disclosure: Past performance is no guarantee of future results. No recommendation or advice is being given as to whether any investment is suitable for a particular investor. Any views or opinions expressed above may not reflect those of Seeking Alpha as a whole. Seeking Alpha is not a licensed securities dealer, broker or US investment adviser or investment bank. Our analysts are third party authors that include both professional investors and individual investors who may not be licensed or certified by any institute or regulatory body.
CCC Intelligent Solutions zvažuje prodej společnosti a najala Morgan Stanley, která má poradit s procesem prodeje. Firma už oslovila potenciální kupce včetně private equity fondů.
Computer motherboard and chip appear in this illustration taken August 25, 2025. REUTERS/Dado Ruvic/Illustration Purchase Licensing Rights, opens new tab
CompaniesNEW YORK, July 9 (Reuters) - CCC Intelligent Solutions (CCC.O), opens new tab is exploring a sale of the company, according to three people familiar with the matter.
The Chicago-based company, which provides software and AI-powered workflow tools, has hired Morgan Stanley (MS.N), opens new tab to advise on a sale process and has reached out to prospective buyers, including private equity firms, the sources said.
The Reuters Daily Briefing newsletter provides all the news you need to start your day. Sign up here.
CCC and Morgan Stanley did not immediately respond to Reuters' requests for comment.
CCC provides software used by auto insurers, collision repair shops, automakers and parts suppliers to manage accident claims, vehicle repairs and related workflows. The company says its platform connects more than 35,000 businesses across the property-and-casualty insurance ecosystem.
The company's market value has fallen to roughly $3.3 billion from about $6.4 billion a year ago as investors grew concerned about slowing growth, weaker industry claims volumes and slower-than-expected adoption of some of its newer software products. The company's shares have declined about 44% over the past 12 months.
CCC has explored a sale before. Reuters reported in 2022 that the company was considering strategic options including a potential sale after attracting takeover interest, though no transaction materialized.
Reporting by Milana Vinn in New York; editing by Colin Barr and Nia Williams
Our Standards: The Thomson Reuters Trust Principles., opens new tab
Milana Vinn reports on technology, media, and telecom (TMT) mergers and acquisitions. Her content usually appears in the markets and deals sections of the website. Milana previously worked at GLG and PE Hub, where she spent several years covering TMT deals in private equity. She graduated from CUNY Graduate School of Journalism with Masters in Business Journalism.
Bausch + Lomb ukončí vývoj glaukomových očních kapek poté, co ve studii ve střední fázi nesplnily hlavní cíl. Akcie v USA po uzavření trhu klesly o 2,8 %.
CompaniesJuly 9 (Reuters) - Bausch + Lomb (BLCO.TO), opens new tab said on Thursday its glaucoma eye drop had missed the main goal in a mid-stage trial of replicating visual function improvements observed in a smaller study.
The company said it will discontinue development of the eye drops for glaucoma-related vision improvement.
Jumpstart your morning with the latest legal news delivered straight to your inbox from The Daily Docket newsletter. Sign up here.
Here are further details: -
Bausch acquired the eye drop BL1107 through a buyout of Whitecap Biosciences last year.
U.S.-listed shares of the company were down 2.8% in extended trading.
The company said it will continue pursuing a sustained-release implant for the treatment of vision-threatening diseases, with a primary focus on geographic atrophy, an advanced, late stage of dry age-related macular degeneration.
Bausch expects clinical trials of the implant to begin in 2028.
"We’ve intentionally built a diversified pipeline ... not every program will succeed, but every study helps us make smarter decisions about where to invest,” said Bausch's medical chief Yehia Hashad.
Reporting by Puyaan Singh in Bengaluru; Editing by Tasim Zahid
Our Standards: The Thomson Reuters Trust Principles., opens new tab
Tilray Medical zahájila komerční prodej svého prvního léčebného konopí v Panamě. Produkt Tilray Oral Solution CBD100 bude dostupný na lékařský předpis prostřednictvím sítě Farmacias Arrocha.
PANAMA CITY, July 09, 2026 (GLOBE NEWSWIRE) -- Tilray Medical, a division of Tilray Brands, Inc. (NASDAQ: TLRY; TSX: TLRY) and a leading global medical cannabis company, today announced the commercial launch of its first medical cannabis product in Panama, marking a significant milestone in the company’s ongoing global expansion and commitment to improving patient access to pharmaceutical-grade cannabinoid medicines worldwide.
The launch follows the successful shipment of Tilray Oral Solution CBD100 from Tilray Medical’s EU-GMP-certified production facilities in Portugal through its joint venture with Solana Life Group S. de R.L. The product is intended to be distributed through Farmacias Arrocha, one of Panama’s leading pharmacy networks, where patients will be able to access Tilray Oral Solution CBD 100 under medical prescription. This is expected to provide patients and healthcare professionals with access to regulated, pharmaceutical-quality medical cannabis through established healthcare channels.
The milestone reinforces Tilray Medical’s position as one of the most geographically diversified medical cannabis companies globally. Today, Tilray Medical serves patients across more than 20 countries spanning Europe, Australia, Canada, Latin America, and other emerging international markets, helping advance access to safe, high-quality cannabinoid-based medicines through regulated healthcare systems.
Rajnish Ohri, President, International, Tilray Brands, stated, “At Tilray Medical, we believe every patient deserves access to safe, consistent, pharmaceutical-grade medical cannabis products. Our commercial launch in Panama reflects our broader vision to expand access to cannabinoid-based medicines through trusted healthcare systems around the world. As medical cannabis frameworks continue to advance, we are committed to working alongside healthcare providers, regulators, pharmacists, and patients to help shape the future of responsible access, advance medical education, and deliver high-quality treatment options that improve lives.”
The launch supports Panama’s emerging medical cannabis framework established under Law 242 of 2021 and follows important regulatory advancements by the Ministry of Health, including Resolution No. 0406 of May 12, 2026, which established key requirements for patient access. The Ministry also recently introduced the Medical Cannabis Users and Authorized Caregivers Identification System (SIUCMAA), creating a structured pathway for physician authorization and patient registration.
Manufactured in Portugal in accordance with rigorous European Union Good Manufacturing Practice (EU-GMP) standards, Tilray Oral Solution CBD100 is intended for use, where authorized, in patients with qualifying medical conditions authorized under Panamanian legislation. The product reflects Tilray Medical’s longstanding commitment to pharmaceutical quality, product consistency, patient safety, and regulatory compliance.
Tilray Medical’s advanced cultivation and manufacturing facilities in Portugal serve as a strategic global export hub, supplying EU-GMP-certified medical cannabis products to regulated markets around the world. The platform enables Tilray Medical to efficiently support growing international demand while maintaining the highest pharmaceutical manufacturing standards across its global operations.
The Panama launch represents another step in Tilray Medical’s broader strategy to expand access across Latin America, an emerging medical cannabis region. As governments across the region continue to establish regulatory pathways for cannabinoid-based medicines, Tilray Medical is well-positioned to support healthcare systems with trusted products, scientific expertise, and a proven track record of operating in highly regulated international markets.
As global acceptance of medical cannabis continues to accelerate, Tilray Medical remains focused on advancing patient care, supporting clinical education, investing in research, and expanding access to high-quality medical cannabis products that help address unmet patient needs worldwide.
For further information, please visit: www.Solana.pa
About Tilray Medical
Tilray Medical is dedicated to transforming lives and fostering dignity for patients in need through safe and reliable access to a global portfolio of medical cannabis brands, including Tilray Medical, Good Supply, Redecan, ARX, and Broken Coast. Tilray grew from being one of the first companies to become an approved licensed producer of medical cannabis in Canada to building the first GMP-certified cannabis production facilities in Europe, first in Portugal and later in Germany. Today, Tilray Medical is one of the largest suppliers of medical cannabis to patients, physicians, hospitals, pharmacies, researchers, and governments, in 20 countries and across five continents.
For more information on Tilray Medical, visit Tilray Medical Europe, Tilray Medical Canada, Tilray Medical Australia-New Zealand and Solana.pa in Panama.
About Tilray Brands
Tilray Brands, Inc. (“Tilray”) (Nasdaq: TLRY; TSX: TLRY), is a leading global lifestyle and consumer packaged goods company with operations in Canada, the United States, Europe, Australia, and Latin America that is leading as a transformative force at the nexus of cannabis, beverage, wellness, and entertainment, elevating lives through moments of connection. Tilray’s mission is to be a leading premium lifestyle company with a house of brands and innovative products that inspire joy and create memorable experiences. Tilray’s unprecedented platform supports over 40 brands in over 20 countries, including comprehensive cannabis offerings, hemp-based foods, and craft beverages.
For more information on how we are elevating lives through moments of connection, visit Tilray.com and follow @Tilray on all social platforms.
Forward-Looking Statements
Certain statements in this communication that are not historical facts constitute forward-looking information or forward-looking statements (together, “forward-looking statements”) under Canadian securities laws and within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended, that are intended to be subject to the “safe harbor” created by those sections and other applicable laws. Forward-looking statements can be identified by words such as “forecast,” “future,” “should,” “could,” “enable,” “potential,” “contemplate,” “believe,” “anticipate,” “estimate,” “plan,” “expect,” “intend,” “may,” “project,” “will,” “would” and the negative of these terms or similar expressions, although not all forward-looking statements contain these identifying words. Certain material factors, estimates, goals, projections, or assumptions were used in drawing the conclusions contained in the forward-looking statements throughout this communication. Forward-looking statements include statements regarding our intentions, beliefs, projections, outlook, analyses, or current expectations concerning, among other things, the Company’s ability to commercialize new and innovative products worldwide. Many factors could cause actual results, performance, or achievement to be materially different from any forward-looking statements, and other risks and uncertainties not presently known to the Company or that the Company deems immaterial could also cause actual results or events to differ materially from those expressed in the forward-looking statements contained herein. Forward‑looking statements in this communication also include statements regarding the Company’s market positioning, ability to meet evolving medical cannabis demand in regulated pharmaceutical environments, and expectations concerning the effectiveness of strategic partnerships, including the Company’s collaboration with Molteni to support the development of the Italian medical cannabis market. For a more detailed discussion of these risks and other factors, see the most recently filed annual information form of Tilray and the Annual Report on Form 10-K (and other periodic reports filed with the SEC) of Tilray made with the SEC and available on EDGAR. The forward-looking statements included in this communication are made as of the date of this communication and the Company does not undertake any obligation to publicly update such forward-looking statements to reflect new information, subsequent events, or otherwise unless required by applicable securities laws.
PepsiCo potvrdila celoroční výhled a uvedla, že první pololetí přineslo téměř 7% růst tržeb, zatímco globální objemy stouply o 3 % v potravinách a o 2 % v nápojích. Severní Amerika ale zůstala slabší kvůli vyšším cenám benzínu.
PepsiCo’s Dividend Could Turn Patience Into Real ProfitPepsiCo NASDAQ: PEP executives reaffirmed the company’s full-year outlook during its 2026 second-quarter earnings question-and-answer session, pointing to strong international momentum and improving global volumes while acknowledging that North America, particularly impulse channels tied to gasoline purchases, performed below expectations in the quarter.
Chairman and CEO Ramon Laguarta said PepsiCo’s first-half results showed “almost 7% revenue growth,” with global volumes up 3% in foods and 2% in beverages, which he described as the company’s fastest volume growth since 2022. CFO Steve Schmitt said reported EPS grew 6% in the first half, while constant-currency EPS rose 3%.
Get PepsiCo alerts:
These 5 Companies Just Made a Massive Bet on ThemselvesStill, management repeatedly cited a softer-than-expected North American environment in the second quarter, with higher gasoline prices affecting consumer behavior and convenience-store purchasing. Laguarta said the company continues to see strong international performance and expects North America to gradually improve in the second half, though at “a more moderate pace” than previously anticipated.
North America Focuses on Affordability, Portfolio Changes A key topic on the call was PepsiCo Foods North America, where volume was flat in the quarter despite stepped-up affordability initiatives and innovation. Laguarta said the company had two main goals for its U.S. foods business: get the salty-snacks category back to volume growth and regain volume share. He said PepsiCo has made progress on both.
Campbell's Soup Stock: Deep Value and a 7% Dividend Yield“A category that was negative in volume now is positive in volume,” Laguarta said. “We were losing share in volume. We’re gaining share in volume.”
Management said the turnaround is being driven by two pillars: price and affordability investments, and growth in “permissible” products and portion-control offerings. Laguarta said the permissible foods portfolio is already a $3 billion business and is growing “almost double digit.” He also pointed to portion-control formats and opening price points in multipacks and variety packs as areas that are working well.
At the same time, Laguarta said PepsiCo needs to improve the return on some of its pricing investments in the second half. He described the work as customer-by-customer and channel-by-channel, with different approaches needed for high-low retailers versus everyday-low-price retailers.
“It’s trying to get more volume from the investments,” Laguarta said in response to a question about what optimizing return on investment means.
Gas Prices Weigh on Convenience and Impulse Channels Executives said higher gasoline prices following the Iran war had a meaningful impact on consumers, not just in the U.S. but globally. Laguarta said the U.S. effect has been most visible in impulse channels such as convenience stores and independent outlets, where PepsiCo is seeing slower conversion of store traffic into food and beverage purchases.
To address the issue, PepsiCo is working with retail partners on offers such as bundles, meal-linked promotions and combined food-and-beverage solutions. Laguarta said the company sees benefits when it has “good offers and bundles” in the channel.
He also said PepsiCo is not trying to raise prices in single-serve products to pay for investments in take-home formats.
“That’s not what we’re trying to do,” Laguarta said.
Asked about test-market work that supported the company’s affordability strategy, Laguarta said the consumer is “worse than what we had anticipated,” largely because of gasoline prices, and that some price investments at certain customers experienced execution delays for commercial reasons. He said those issues have been addressed and should support acceleration in the second half.
Guidance Reaffirmed, Tariff Refunds to Offset Cost Pressure Schmitt said PepsiCo reaffirmed its full-year guidance, though he noted results may trend toward the low end of the EPS range the company had previously provided. He said management expects international net revenue to remain strong, North America to gradually improve and commodity pressures to increase.
PepsiCo also expects refund claims for tariffs paid last year to provide about 1 full point of EPS growth for the year. Schmitt said those refunds will help offset commodity pressure and allow the company to continue investing in the business.
“We’re not making decisions that hurt the top line in our assessment,” Schmitt said. He added that North America advertising and marketing expense is projected to increase in the second half compared with the prior year.
Schmitt said third-quarter results are expected to benefit from international strength and approximately 1 point of EPS benefit from tariff refund claims, but also face a higher year-over-year tax rate and timing of certain costs and investments. He said PepsiCo expects more productivity in the fourth quarter than in the third quarter.
International Business Remains a Growth Driver Management emphasized the strength of PepsiCo’s international business throughout the call. Laguarta said the international business is expected to cross $40 billion this year and has become a major contributor to company volume, revenue and profit. He said international beverage volumes represent about two-thirds of PepsiCo’s total company beverage volume, while international foods volumes represent more than half.
Laguarta said markets in Asia and the Middle East remained resilient despite concerns about elevated gasoline prices. He also cited strong performance in Europe, where World Cup sponsorship activity in the food business is helping activate the category, and said Latin America was growing somewhat less than the rest of the business but remained positive.
Schmitt said international operating margin increased by a full point in the second quarter, showing not only top-line growth but improved flow-through on the profit and loss statement. He noted that PepsiCo expects some commodity inflation in the second half, particularly in EMEA, but said teams have been proactive in mitigation efforts.
PBNA Margins, M&A and U.S. Productivity Initiatives In PepsiCo Beverages North America, Schmitt said operating margin declined about 90 basis points in the quarter, driven by gross profit rate. He attributed about half of the gross profit rate decline to the company’s Alani commercial arrangement, with additional pressure from softness in convenience and gas channels and product mix.
Laguarta said PepsiCo continues to see momentum in no-sugar beverages, functional hydration and energy, as well as innovation expected to scale in the second half.
On recent acquisitions, Laguarta said both Siete and poppi are “doing well.” He said poppi experienced some transition impact as it moved from its prior distributor system into PepsiCo’s system, but that issue is “pretty much solved.” Siete had ingredient-related issues in April and May, which he said have also been resolved. He also cited partnerships such as Celsius and Alani Nu as ways PepsiCo is expanding consumer offerings.
Executives also discussed productivity initiatives in the U.S., including automation, digitalization and efforts to combine scale across the company’s North American food and beverage businesses. Laguarta said PepsiCo is testing combined mixing centers, combined delivery and combined fleet concepts in Texoma, with more detail expected later this year or early next year.
Laguarta said the objective is to fund U.S. transformation without reducing investment in international markets, which he described as PepsiCo’s largest long-term growth opportunity.
About PepsiCo NASDAQ: PEPPepsiCo, Inc NASDAQ: PEP is a multinational food and beverage company headquartered in Purchase, New York. The company develops, manufactures, markets and sells a broad portfolio of branded food and beverage products, including carbonated and noncarbonated soft drinks, bottled water, sports drinks, juices, ready-to-drink teas and coffees, salty snacks, cereals, and other convenient foods. Its leading consumer brands include Pepsi, Mountain Dew, Gatorade, Tropicana, Quaker, Lay's, Doritos and Cheetos, among others.
Formed through the 1965 merger of Pepsi-Cola and Frito-Lay, PepsiCo has grown into a global business with integrated manufacturing, distribution and marketing operations.
This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to [email protected].
Should You Invest $1,000 in PepsiCo Right Now?Before you consider PepsiCo, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and PepsiCo wasn't on the list.
While PepsiCo currently has a Hold rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Click the link to see MarketBeat's list of seven stocks and why their long-term outlooks are very promising.
BD oznámila, že 6. srpna v 8:00 ET uspořádá audio webcast k hospodářským výsledkům za 3. čtvrtletí fiskálního roku 2026. Firma zároveň zveřejní souhrnné finanční informace a aktualizaci provozu a strategie.
Resources Investor Relations Journalists Agencies Client Login Send a Release News Products Contact , /PRNewswire/ -- BD (Becton, Dickinson and Company) (NYSE: BDX), a leading global medical technology company, today announced that BD management will host an audio webcast at 8 a.m. ET on Thursday, August 6, 2026 to discuss the Company's financial results for its third quarter of fiscal year 2026, which ended on June 30, 2026, and to provide an update on its operations and strategy. The audio webcast can be accessed at BD's investor relations website at www.bd.com/investors, and a replay will be made available shortly after the call at the same website. Prior to the call, the Company will issue a news release and related presentation materials that will include summary financial information for the quarter. The news release and related presentation materials will be made available at www.bd.com/investors.
About BD
BD is one of the world's largest pure-play medical technology companies with a Purpose of advancing the world of health™ by driving innovation across medical essentials, connected care, biopharma systems and interventional. The company supports those on the frontlines of healthcare by developing transformative technologies, services and solutions that optimize clinical operations and improve care for patients. Operating across the globe, with more than 60,000 employees, BD delivers billions of products annually that have a positive impact on global healthcare. By working in close collaboration with customers, BD can help enhance outcomes, lower costs, increase clinical efficiency, improve safety and expand access to healthcare. For more information on BD, please visit bd.com or connect with us on LinkedIn at www.linkedin.com/company/bd1/, X @BDandCo or Instagram @becton_dickinson.
Costco Wholesale Corporation (NASDAQ:COST, XETRA:CTO) shares fell about 4% to $913 on Wednesday after the warehouse retailer reported a moderation in June comparable sales growth, though Bank of America analysts maintained their ‘Buy’ rating, arguing the company's value-focused strategy and affluent customer base should continue to support market share gains.
For the five weeks ended July 5, total sales rose 10.6%, while US comparable sales excluding gasoline increased 7.6%. Bank of America noted the result represented a slowdown on both a one-year and two-year stacked basis following a stronger May.
The analysts wrote that Costco's "philosophy of leading with value and its weighting towards a higher income consumer gives us confidence share gains across categories will continue."
Non-food comparable sales increased by a mid- to high-single-digit percentage, driven by jewelry, home furnishings and major appliances. Management also highlighted higher prices in consumer electronics and appliances due to inflation in memory chip prices.
Fresh food comparable sales rose by a mid-single-digit percentage, supported by bakery and meat, while food and sundries posted low- to mid-single-digit growth led by food, candy and frozen products.
Overall inflation remained in the low- to mid-single-digit range, with food inflation at the lower end due to egg price deflation and non-food inflation at the higher end because of rising memory prices.
Customer traffic increased 3.2% during the month, easing from 3.9% in May, while average ticket growth excluding gasoline and foreign exchange was 3.7%, compared with 4% in the prior month.
Bank of America also noted Costco is now lapping the rollout of extended shopping hours introduced last July for executive members and later for all members. Management previously estimated the additional hours contributed roughly one percentage point to weekly US sales following their introduction.
Elsewhere, ancillary sales growth slowed as gasoline prices eased, while comparable sales growth moderated in Canada and other international markets. Digital comparable sales remained strong, rising 21.5% in June and improving sequentially from the previous month.
The analysts also noted Costco shifted its member appreciation days to coincide with Amazon's Prime Day and other competing promotional events.
Palantir v 1. čtvrtletí meziročně zvýšil tržby o 85 % a provozní marže vzrostla na 60 %. Wall Street má cílovou cenu 200 USD, asi o 54 % nad aktuální cenou.
Palantir Technologies (PLTR 2.47%) was a retail investor darling in 2023, 2024, and 2025. The stock soared 2,670% during that period, despite Wall Street analysts suggesting the price was already too high for most of it. But the stock has taken a tumble since the end of 2025, dropping roughly 37% from its November 2025 all-time high amid the broader software-as-a-service (SaaS) stock sell-off.
Meanwhile, analysts have begun to take a fresh look at the company as it continues to deliver phenomenal revenue growth and earnings. In fact, despite a recent rally in the stock, the average Wall Street price target is significantly above the current price.
Image source: Getty Images.
How high can Palantir climb? Palantir continues to defy expectations with its revenue growth and improving profitability. Revenue accelerated once again in the first quarter, with its top-line climbing 85% year over year in the first quarter. It's showing particular strength in its U.S. business, and its backlog of remaining deal value shows strong momentum and a long runway for continue revenue growth. Overall, adjusted operating margin expanded to 60%. Management also raised its full-year guidance along with those earnings results.
The software business should continue to produce very strong operating leverage. Its research and development expenses fell to less than 10% of revenue in the first quarter. Meanwhile, the company has taken a strategic approach to sales, letting the software speak for itself for the most part. It has recently turned to boot camps to show companies and their employees how to use Palantir's software to improve operations, a move that has been extremely effective in driving customer acquisition.
Palantir seemingly has no equal to compare its software against. The threat of AI labs supplanting existing enterprise software at a lower cost seems even less likely for Palantir than for more basic software solutions. The core of Palantir is its ontology framework, which enables users to find meaningful connections between disparate data sets. The artificial intelligence built into Palantir's platform isn't easily replicated. As a result, Palantir should see high revenue retention rates.
Today's Change
(
-2.47
%) $
-3.27
Current Price
$
128.95
Execution and growth have never been a problem for Palantir. The biggest concern with the stock has always been its valuation. After the sell-off, the stock trades at 43 times next year's sales expectations and 93 times forward earnings. That's a huge premium over the market. Nonetheless, analysts think it's too cheap.
The median price target for Palantir stock on Wall Street is $200 per share. That price is roughly 54% above the stock's current price as of this writing. And if it reaches that price within 12 months, the stock would trade at roughly the same forward P/E as today, based on analysts' estimates. That suggests Wall Street sees a lot more growth to come for the business.
While management has produced excellent results over the last few years, there's only so long revenue and earnings can accelerate. When the slowdown arrives, the stock could take a hit. Whether you should buy Palantir today depends on whether you think the company can continue to efficiently attract new customers and expand its market at scale.
Micron ztratil za méně než dva týdny přes 20 % hodnoty, ale tržby ve fiskálním 3. čtvrtletí meziročně vzrostly více než čtyřnásobně a výhled na fiskální 4. čtvrtletí počítá s více než 20% sekvenčním růstem.
Micron (MU +4.55%) has lost more than 20% of its value in less than two weeks amid a broader correction among AI stocks. Most investors have been conditioned to expect these sorts of stocks to keep rising steadily, especially as tech giants continue to ramp up their AI infrastructure spending.
The fundamentals of its business suggest Micron's stock rally should continue, so when its price movements defy expectations, it creates buying opportunities for long-term investors.
Image source: Getty Images.
Micron's combination of valuation and revenue growth is rare Micron may be in a class of its own when it comes to valuation and revenue growth.
In its fiscal 2026 third quarter, which ended May 28, the company more than quadrupled its revenue year over year, blowing past its previous guidance. Even its fiscal fourth-quarter guidance was solid, with more than 20% sequential growth expected.
Today's Change
(
4.55
%) $
43.22
Current Price
$
992.02
Yet the stock trades at a P/E ratio of 22, which is lower than the S&P 500's (^GSPC +0.81%) valuation. Meanwhile, few companies in the benchmark index came anywhere close to that kind of revenue growth. The valuation appears even more absurd when looking at Micron's 6.4 forward P/E ratio. That metric reflects expected future growth, making the current dip all the more jarring.
The company even hinted in its earnings release a few weeks ago that it is breaking free from the cyclical nature of the memory chip business. "Multiyear Strategic Customer Agreements will significantly enhance the durability and predictability of Micron's strong financial performance," said CEO Sanjay Mehrotra.
The fundamentals are strong and strengthening, which makes the recent stock price slide more difficult to justify. It also comes as fellow memory product provider Samsung reported a higher quarterly profit than Apple or Nvidia. Micron is riding that same tailwind and looks poised to expand its market share.
Micron's top customers are rushing to spend more on AI infrastructure The string of strong quarters that Micron has put up lately has not been a fluke. They are the result of the company's largest customers ramping up their AI expenditures and competing with each other to gain market share in lucrative opportunities.
Amazon recently said it would issue at least $25 billion in corporate bonds to raise funds for its AI infrastructure build-out. Meanwhile, Alphabet completed an $84.75 billion equity raise a little earlier.
This spending comes from highly profitable companies that are scaling up their products and services thanks to AI. A meaningful portion of the money raised by their financial moves should flow rapidly into Micron's coffers since AI servers require copious amounts of memory chips.
Micron is even well positioned for the expected push into physical AI. Humanoid robots and self-driving vehicles will also need Micron's memory chips. While hyperscalers' big deals get the most attention, Micron also struck a multiyear agreement with Ford Motor Company to supply the memory products for its next-gen vehicles. Deals can branch well beyond tech giants as more industries embrace AI. It all bodes well for Micron despite the recent stock price action.
Marc Guberti has positions in Apple. The Motley Fool has positions in and recommends Alphabet, Amazon, Apple, Micron Technology, and Nvidia. The Motley Fool has a disclosure policy.
Philip Morris získal od FDA povolení uvádět na trh 20 variant nikotinových sáčků Zyn jako méně škodlivou alternativu ke kouření. Morgan Stanley i Bank of America následně zvýšily cílové ceny akcie.
Wall Street investors are reportedly flooding back into tobacco stocks, erasing years of ethical boycotts as the industry’s aggressive pivot toward smoke-free products blurs old moral lines.
For nearly a decade, pension funds and major endowments blacklisted cigarette makers under strict mandates.
But that taboo is quickly going up in smoke. Tobacco companies generating massive sales from non-combustible alternatives are “rejoining polite society” and earning premium stock market valuations from returning institutional capital, the Wall Street Journal reported Thursday.
Alternative tobacco products have sparked a rethink among investors after nearly a decade of ESG-related concerns. Christopher Sadowski The shift gained fresh momentum when the Food and Drug Administration gave the green light for Philip Morris to market 20 variants of its Zyn nicotine pouches as a less harmful alternative to traditional smoking. The June 30 decision noted a reduced risk of lung cancer, stroke and heart disease for people who use the pouches, which go between one’s gums and cheek but don’t contain tobacco.
The move came just weeks after New York Gov. Kathy Hochul signed a new 75% wholesale tax into law on alternative tobacco products — the so-called “Bro Tax.”
Still, crossing the FDA’s regulatory moat prompted immediate action from major investment banks. Morgan Stanley recently raised its price target on Philip Morris to $200, highlighting the upcoming rollout of Zyn Ultra.
“The developments increase our confidence,” Morgan Stanley analysts wrote in a briefing to clients, adding that they see an increased probability for their $250 bull-case scenario as smoke-free alternatives dominate Philip Morris’ revenue.
Bank of America similarly backed the stock, pushing its target to $209 on high-margin smokeless execution.
British American Toboacco has also been embarking upon a share buyback program in recent months. REUTERS Philip Morris generates about 41% of its sales from non-combustible products, the Journal noted, adding it now trades at a massive 70% premium over rivals still heavily dependent on sales of old-fashioned smokes.
While Philip Morris has captured the premium valuations, rival British American Tobacco, or BATm is executing a sweeping, tech-driven transformation to reclaim market share.
The maker of Lucky Strike and Vuse vapes reportedly plans to eliminate 9,000 global jobs — nearly 19% of its workforce — by outsourcing 3,500 roles to Accenture and deploying artificial intelligence to automate back-office operations.
The workforce cuts aim to harvest $800 million in annual savings by 2028, freeing up capital to aggressively fund BAT’s smokeless product expansion.
Wall Street experts are bullish on tobacco stocks, seeing huge growth potential in alternatives to regular cigarettes and AI-related cost savings. LightRocket via Getty Images Barclays analyst Pallav Mittal noted that the “scale of this workforce reduction is unexpected.”
Nevertheless, the strategic shift keeps analysts bullish.
Experts at Jefferies and UBS recently reiterated buy ratings on BAT, joining a solid majority of Wall Street analysts who rate the stock a strong buy as the firm pushes to double its share of the US oral nicotine market.
As combustible cigarette volumes maintain their decades-long decline, the industry’s rapid evolution appears to be permanently redrawing the boundaries of institutional investing.
“The FDA authorization for Zyn … is a significant positive,” Morgan Stanley analysts concluded in their recent note upgrading the sector. “It provides a clear regulatory pathway and validates the harm reduction potential increasing our confidence in the company’s ability to drive accelerated smoke-free growth.”
TSMC ve čtvrtek zveřejní výsledky za 2. čtvrtletí; trh čeká tržby ve výši zhruba 40 miliard USD a sleduje hlavně výhled poptávky po AI a kapacity CoWoS.
INDIA - 2023/12/14: In this photo illustration, the Taiwan Semiconductor Manufacturing Co. Ltd (TSMC) logo seen displayed on a mobile phone screen with the AI (artificial intelligence) revolution symbol in the background. (Photo Illustration by Idrees Abbas/SOPA Images/LightRocket via Getty Images)
SOPA Images/LightRocket via Getty Images
Taiwan Semiconductor Manufacturing Company (NYSE: TSM) reports second-quarter earnings on Thursday, July 16, with its earnings conference scheduled for 2:00 p.m. Taipei time (2:00 a.m. ET). The numbers Wall Street is penciling in tell their own story about how far this AI cycle has already run. Consensus estimates call for revenue near $40 billion, up roughly 32% year-over-year, with earnings per ADR unit expected to rise more than 50% from a year ago. TSMC itself guided to revenue between $39.0 billion and $40.2 billion, with gross margin in a 65.5% to 67.5% range.
What makes this print more interesting than a routine beat-and-raise is not the top line. TSMC has cleared elevated bars all year, leading many to name it among the best AI infrastructure plays for 2026. The real question is what management says about the back half of the year, and whether the company is finally catching up to the tsunami of demand it has been chasing for two years.
What The Market Wants to HearInvestors will be listening for three things on the call.
First, whether TSMC lifts its full-year revenue growth guidance, which currently stands at "above 30%" in dollar terms. Citi and other sell-side shops expect an upward revision given management's April commentary about "extremely robust" AI demand. Second, whether the company raises its 2026 capital budget above the high end of its existing $52 billion to $56 billion range, which would signal even more urgency to add capacity. Third, and most closely watched, is an update on advanced packaging — specifically CoWoS. This technology binds logic chips to high-bandwidth memory and has become the true chokepoint in AI chip production.
There is a modest note of caution heading into the print. TSMC's combined April and May revenue grew about 24% year-over-year, short of the roughly 35% growth some investors had penciled in for the quarter, which has introduced some near-term jitters even as the longer-term growth story remains intact.
MORE FOR YOU
At the Center of AI Infrastructure BuildoutIt is difficult to overstate how central TSMC has become to the infrastructure race now underway among the major cloud platforms. Amazon (NASDAQ: AMZN), Microsoft (NASDAQ: MSFT), Alphabet (NASDAQ: GOOGL) and Meta Platforms (NASDAQ: META) are together on pace to spend about $700 billion on capital expenditure this year, up roughly three-quarters from 2025.
The bulk of that money is flowing into AI data centers, custom silicon and the GPUs that TSMC alone has the capacity to manufacture at scale. Nearly every leading AI accelerator — Nvidia's (NASDAQ: NVDA) GPUs, AMD's (NASDAQ: AMD) MI-series chips, and the custom ASICs designed in-house by Google and Amazon — is fabricated on TSMC's advanced nodes and finished in TSMC's packaging lines. That concentration is precisely why TSMC's order book is a telltale gauge of AI infrastructure demand more broadly, arguably more informative than any single hyperscaler's earnings call.
The Bottleneck Has Moved from Silicon to PackagingFor most of the last two decades, the constraint in this industry was the ability to shrink transistors. That is no longer true. TSMC's 3-nanometer and 2-nanometer processes are running at high yields. The harder problem now is CoWoS advanced packaging, which stacks logic dies with high-bandwidth memory into the modules that actually ship inside an AI server. Nvidia alone has reportedly secured roughly 60% of TSMC's CoWoS output for 2026, leaving other GPU and ASIC makers to scrap for what remains. Some customers have reportedly turned to Samsung Electronics (KRX: 005930) to supplement capacity TSMC cannot provide.
TSMC has responded with one of the more aggressive capacity buildouts in its history, targeting a compound annual growth rate above 80% for CoWoS capacity between 2022 and 2027, adding packaging campuses in Tainan and Chiayi, and planning a packaging hub in Arizona to serve U.S. customers directly. Industry trackers estimate the gap between packaging supply and demand, which ran as wide as 20% earlier this year, could narrow to roughly 10% by the end of 2026 as this new capacity comes online. This means that packaging, not wafer starts, is likely to remain the variable that determines how quickly new AI hardware actually reaches customers through the rest of this year.
The Great Semiconductor Onshoring ExperimentThe risks here are less about demand, which by every account remains extraordinary, and more about execution. TSMC's own disclosures flag U.S. export controls, evolving tariff policy, and customer concentration as ongoing risks to monitor.
The Arizona expansion, now framed as a $465 billion, eleven-fab program tied to a U.S.-Taiwan tariff framework, has become the highest-profile test case for reshoring chip manufacturing in America at scale. Taiwan's National Development Council has pointed to challenges including water availability in the Arizona desert, visa delays for the Taiwanese engineers rotating through on assignment, and long-term power supply as the practical constraints management is managing in real time. None of these are new problems for U.S. semiconductor manufacturing, but the scale of what TSMC is attempting in Arizona means any one of them could push a fab timeline by quarters or even years.
Consumer Device InflationThe other thread worth watching is pricing.
TSMC has told major customers, including Apple (NASDAQ: AAPL), Nvidia and Qualcomm (NASDAQ: QCOM), to expect a fourth consecutive year of price increases starting in 2026, with hikes reportedly running 3% to 10% depending on the node and application, and now extending beyond 2-nanometer and 3-nanometer wafers to nodes as mature as 7-nanometer. A 2-nanometer wafer now runs upward of $30,000, more than 50% above the cost of a 3-nanometer wafer, and TSMC has guided to gross margin dilution of 2 to 3 percentage points this year from the 2-nanometer ramp and overseas expansion, even as pricing offsets much of that pressure.
For now, TSMC's biggest AI customers appear able to absorb these increases. Nvidia's margins remain wide enough to pass costs through, and demand for accelerators has shown little price sensitivity.
But further downstream, the picture is different. Smartphone and PC chipmakers operating on thinner margins are expected to pass a meaningful share of these increases on to consumers, which is one reason, along with surging prices for memory, analysts expect flagship device prices to tick higher starting later this year. It is a useful reminder that the AI capital cycle, for all its abstraction on a spreadsheet, is already showing up in the price of an iPhone or a laptop.
Managing High-Quality ProblemsWherever Q2 results land, TSMC is for the moment sitting in the catbird seat during the biggest capex cycle of this century.
They operate at the technological frontier of semiconductor fabrication worldwide. They work with the most desirable customers, and those customers fight to get allocations of their capacity. More significantly, they have built a “trust moat” based on years of meeting commitments, engineering excellence, and protecting customer IP that sets them apart from their closest competitors, Samsung Foundry and Intel.
The challenges TSMC faces reflect the ordinary friction of building enormous capacity and talent at record speed, and they are better positioned than anyone to manage them.
Their CEO C.C. Wei has burnished his credibility through a combination of bullish capital commitments to expansion, made after months of channel checks with major customers, and frank discussions about the risk of industry overcapacity. For this reason, analysts will be hanging on his every word to divine how long the AI Supercycle is likely to persist.
Hlavní právní zástupce Coinbase Paul Grewal po šesti letech odchází. Firma zároveň jmenuje Molly Abraham novou hlavní právní zástupkyní s titulem general counsel.
The Coinbase logo on a smartphone screen in this illustration taken November 3, 2025. REUTERS/Dado Ruvic/Illustration Purchase Licensing Rights, opens new tab
CompaniesWASHINGTON, July 9 (Reuters) - Coinbase (COIN.O), opens new tab's Chief Legal Officer Paul Grewal is stepping down after six years at the U.S. crypto giant where he fought off a landmark suit brought by the U.S. securities regulator and played an instrumental role in the crypto industry's Washington campaign to secure industry-friendly policies.
Grewal will step down effective immediately, with Molly Abraham, Coinbase's vice president of legal, moving into his role with the title of general counsel, the company told Reuters. Coinbase is also naming Ryan VanGrack, who is currently vice president of legal, as the company's first vice chair and head of corporate affairs, Coinbase said.
The Reuters Daily Briefing newsletter provides all the news you need to start your day. Sign up here.
Grewal first posted news of his departure on X.
Grewal's time at Coinbase was partly defined by a years-long legal battle with the Securities and Exchange Commission, which sued Coinbase in 2023 alleging the company had flouted its rules by facilitating trading in crypto tokens that it said should have registered as securities with the watchdog.
Legal experts saw the case as existential for Coinbase and the broader crypto industry, which had long sought to avoid costly SEC oversight. The agency under U.S. President Donald Trump, who courted crypto money on the campaign trail, dismissed the case last year, a massive win for Grewal, Coinbase and the industry.
Coinbase has been a top advocate for the crypto industry as it has sought policy changes in Washington to put it on a solid legal footing, with Grewal at the forefront of those efforts.
Most recently, he had also been involved in deliberations on highly anticipated legislation -- dubbed the Clarity Act -- that would create federal rules for cryptocurrencies. The bill had been bogged down for months by a dispute between crypto companies and banks, but advanced out of a key Senate committee in May.
"After helping to take the company public, fighting the SEC and winning, moving us from Delaware to Texas, working to get GENIUS and soon CLARITY passed into law, and so much more – now is my time for new adventures," Grewal said in a post on X.
In his new role, VanGrack, who will be second-in-command to CEO Brian Armstrong, will step into a "broader corporate and public-facing role" representing Coinbase before "key stakeholders and policymakers around the world," he said in an interview.
The company needs to focus "on steps that unlock products, expand jurisdictions, and enhance our relationships with governments and partners around the world," VanGrack added.
The shift comes as Coinbase looks to become an "everything exchange" by expanding beyond crypto, including into stock trading, prediction markets and artificial intelligence-powered investment tools.
“What I'm so excited about in this next chapter is this is all about building our products... because of the path that [Grewal] cleared," said Abraham in an interview.
Reporting by Hannah Lang; editing by Michelle Price
Our Standards: The Thomson Reuters Trust Principles., opens new tab
Hannah Lang covers financial technology and cryptocurrency, including the businesses that drive the industry and policy developments that govern the sector. Hannah previously worked at American Banker where she covered bank regulation and the Federal Reserve. She graduated from the University of Maryland, College Park and lives in Washington, DC.
Clover Health oznámila, že výsledky za 2. čtvrtletí 2026 zveřejní po uzavření trhu 5. srpna 2026. Téhož dne v 17:00 ET uspořádá webcast k hospodářským výsledkům.
WILMINGTON, Del., July 09, 2026 (GLOBE NEWSWIRE) -- Clover Health Investments, Corp. (Nasdaq: CLOV) (“Clover,” “Clover Health” or the “Company”), today announced that it will release its financial results after the market closes on Wednesday, August 5, 2026. The Company’s management will host a webcast presentation at 5:00 p.m. Eastern Time on the same day to discuss the company’s business and financial performance for the quarter.
Second Quarter 2026 Conference Webcast Details:
What: Clover Health’s Second Quarter 2026 Earnings Conference CallWhen: Wednesday, August 5, 2026, at 5:00 p.m. Eastern TimeWebcast: To access the webcast, you may register at https://clover-health-2q-2026-earnings.open-exchange.net/.
A live and archived webcast of the conference call will also be accessible from the Investor Relations section of Clover Health’s website at https://investors.cloverhealth.com/ for 12 months.
About Clover Health:
Clover Health (Nasdaq: CLOV) is a physician enablement technology company committed to bringing access to great healthcare to everyone on Medicare. This includes a focus on seniors who have historically lacked access to affordable, high-quality healthcare. Our strategy is powered by our software platform, Clover Assistant, which is designed to aggregate patient data from across the healthcare ecosystem to support clinical decision-making and improve health outcomes through the early identification and management of chronic disease. For our members, we provide PPO and HMO Medicare Advantage plans in several states, with a differentiated focus on our flagship wide-network, high-choice PPO plans. For healthcare providers outside Clover Health's Medicare Advantage plan, we extend the benefits of our data-driven technology platform to a wider audience via our subsidiary, Counterpart Health, and aim to enable enhanced patient outcomes and reduced healthcare costs on a nationwide scale. Clover Health has published data demonstrating the technology’s impact on Medication Adherence, Congestive Heart Failure, Chronic Obstructive Pulmonary Disease, and in Underserved Populations as well as the earlier identification and management of Diabetes and Chronic Kidney Disease.
Cardinal Health byl vyřazen z indexů Russell 1000 Defensive, Russell 1000 Growth-Defensive a Russell 1000 Value-Defensive kvůli technické reklasifikaci po prudkém růstu akcií, ne kvůli zhoršení fundamentů. Firma dál hlásí růst tržeb i zisku ve specializovaném byznysu.
Key Takeaways Cardinal Health's Russell index removal reflects reclassification, not weakening business fundamentals.CAH's specialty platform and higher-margin businesses continue driving revenue and profit growth.Cardinal Health's pharmaceutical distribution business posted strong growth, supported by specialty demand. Cardinal Health's (CAH - Free Report) removal from the Russell 1000 Defensive, Russell 1000 Growth-Defensive and Russell 1000 Value-Defensive indices may initially appear concerning, but the development is more technical than fundamental. The healthcare distributor's exclusion largely reflects Russell's periodic index reclassification following a sharp appreciation in Cardinal Health's share price, rather than any deterioration in its business performance.
After soaring more than 70% in 2025, the stock has already added another 15.4% year to date. The company’s share price performance so far this year has outperformed the industry’s 0.2% decline and S&P 500 Index’s 9.9% gain.
While index-linked funds tracking these benchmarks may trim their holdings, potentially creating short-term selling pressure, the removal does not signal weakening fundamentals or lower earnings expectations. In fact, sentiment around the company remains constructive, with several Wall Street analysts recently raising their price targets.
YTD Performance of CAH vs Industry
Image Source: Zacks Investment Research
Cardinal Health continues to strengthen its position as one of the three dominant U.S. pharmaceutical distributors alongside McKesson (MCK - Free Report) and Cencora (COR - Free Report) . Its latest quarterly performance reinforced this thesis, as Pharmaceutical and Specialty Solutions once again delivered double-digit revenue and profit growth, while high-margin businesses (including at-Home Solutions, Nuclear & Precision Health Solutions and OptiFreight Logistics) continued to outgrow the core distribution business.
Coupled with sustained healthcare utilization, demographic tailwinds and increasing specialty drug adoption, Cardinal Health's long-term investment case appears driven by operational execution rather than index membership.
Key Drivers of CAH’s GrowthSpecialty Healthcare Platform as a Powerful Growth Engine: Cardinal Health's strategy of expanding beyond traditional pharmaceutical distribution is steadily improving its earnings profile. Specialty revenues are expected to exceed $50 billion in fiscal 2026, supported by rapid expansion of its Specialty Alliance physician network, Solaris integration and growing biopharma solutions capabilities.
The Specialty segment profit continues to outpace revenue growth as higher-margin services complement pharmaceutical distribution. Management also highlighted strong momentum in MSO platforms and Sonexus patient-support services, reinforcing specialty healthcare as a durable multiyear growth driver.
High-Growth Businesses Are Diversifying Profit Sources: Cardinal Health's "Other Growth Businesses" have evolved into meaningful contributors to earnings. Revenues from at-Home Solutions, Nuclear & Precision Health Solutions and OptiFreight Logistics surged 31%, while segment profit climbed 34% during the quarter.
Strong demand for home-based care, theranostics and healthcare logistics continues to support growth. ADS integration, expansion of ContinuCare Pathway and investments in distribution infrastructure further strengthen Cardinal Health's ability to capture secular healthcare trends that extend well beyond traditional drug distribution.
Core Pharmaceutical Distribution Remains Exceptionally Resilient: Despite industry pricing changes, Cardinal Health continues demonstrating impressive operating leverage. Pharmaceutical segment revenues increased 11% to $56.1 billion, while segment profit advanced 18%, benefiting from strong specialty demand, stable generic economics and resilient branded pharmaceutical volumes.
GLP-1 therapies alone contributed six percentage points to quarterly revenue growth. Investments in automation, distribution infrastructure and supply-chain efficiency continue supporting record service levels, positioning the company to capitalize on rising prescription volumes and long-term healthcare demand.
A Glance at CAH’s EstimatesThe Zacks Consensus Estimate for CAH’s fiscal 2026 and 2027 earnings per share (EPS) implies year-over-year growth of 30.6% and 11.3%, respectively, to $10.76 and $11.98. In the past 60 days, the consensus mark for the company's fiscal 2026 EPS has remained stable.
Revenues for fiscal 2026 are projected to grow 15.1% to $256.24 billion and another 8.8% to $278.75 billion in fiscal 2027.
Image Source: Zacks Investment Research
Competition Remains Intense, but Cardinal Health Is Closing the GapCompetition among the "Big Three" distributors remains fierce. McKesson continues to leverage its expanding oncology platform, biopharma services and AI-enabled supply chain while delivering double-digit operating profit growth across specialty businesses. Cencora continues to invest aggressively in specialty pharmaceuticals, MSO platforms and digital transformation while strengthening its global specialty logistics capabilities.
However, Cardinal Health has significantly narrowed the competitive gap through the rapid expansion of its specialty business, strong growth in Nuclear & Precision Health Solutions and accelerating growth in at-Home Solutions. While McKesson currently benefits from a broader oncology portfolio and Cencora continues to expand its global specialty capabilities, Cardinal Health appears increasingly differentiated through its diversified healthcare services portfolio.
As McKesson, Cencora and Cardinal Health continue to invest aggressively in specialty care, competitive intensity is likely to remain elevated across the healthcare distribution landscape.
Risks and ChallengesDespite its strong outlook, several risks warrant attention. Inflation Reduction Act pricing adjustments continue creating revenue headwinds despite limited profit impact. Tariff-related uncertainty remains concentrated within the Global Medical Products and Distribution business, while integration risks surrounding Solaris and ADS acquisitions require successful execution.
Specialty growth also depends on successful physician network expansion and sustained pharmaceutical demand. Additionally, reimbursement reforms, changing drug pricing dynamics and competitive investments by McKesson and Cencora could pressure long-term margins across the healthcare distribution industry.
ConclusionAlthough Russell index removal may trigger temporary passive fund selling, it does not alter Cardinal Health's improving fundamentals. Strong execution across specialty healthcare, pharmaceutical distribution and higher-margin growth businesses support a favorable long-term outlook. While competitive and regulatory risks remain, the company's structural growth drivers remain intact. According to the Zacks Consensus Estimate, the average target price still implies roughly 5.6% upside from current levels.
Image Source: Zacks Investment Research
With a Zacks Rank #3 (Hold), existing CAH investors may find sufficient reasons to retain the stock while monitoring continued execution in its specialty-led growth strategy. You can see the complete list of today’s Zacks #1 Rank (Strong Buy) stocks here.
Agilent rozšiřuje AI software a automatizaci pro biopharmaceutický růst a spouští xCELLigence RTCA eSight AI pro analýzu živých buněk. Ve 3. fiskálním čtvrtletí čeká tržby 1,83–1,85 mld. USD.
Key Takeaways Agilent is expanding its AI software and automation portfolio to support its biopharma growth prospects. Agilent launched xCELLigence RTCA eSight AI to simplify label-free live-cell imaging analysis. A expects fiscal Q3 2026 revenues of $1.83B-$1.85B, implying 5.0%-6.5% reported growth. Agilent Technologies (A - Free Report) shares have lost 5.2% in the year-to-date period, underperforming the Zacks Medical industry's 2.8% growth. The dip reflects cautious laboratory spending and a challenging macroeconomic environment.
However, Agilent continues to strengthen its long-term growth prospects through product innovation and expanding artificial intelligence (AI)-enabled laboratory software and automation capabilities, supported by healthy demand across the pharmaceutical, diagnostics and advanced materials markets.
The company also benefits from growing demand for AI-enabled laboratory software and automation as pharmaceutical and biotechnology companies increasingly digitize research workflows and accelerate drug discovery. Agilent's integrated software ecosystem, led by its OpenLab and xCELLigence platforms, combines analytical instruments, software and laboratory automation to improve productivity, reduce manual intervention and deliver more consistent scientific results.
Agilent Expands AI-Powered Cell Analysis PortfolioAgilent continues to strengthen its AI-enabled laboratory portfolio through innovations spanning analytical instruments, laboratory software, automation and digital workflows, supporting the growing adoption of AI-driven research solutions.
Building on this strategy, the company launched xCELLigence RTCA eSight AI, a new AI-powered software module that simplifies label-free live-cell imaging analysis. The software enhances the xCELLigence RTCA eSight platform by combining AI-driven image analysis with impedance measurements, enabling researchers to analyze imaging and cell behavior simultaneously from the same experiment.
The new module replaces manual cell segmentation and subjective parameter tuning with a one-click automated workflow, helping researchers generate more consistent and reproducible results while reducing analysis time and lowering training requirements. Designed for drug discovery and high-throughput biopharma research, the software is expected to accelerate scientific workflows, improve laboratory productivity and expand adoption of Agilent's integrated cell analysis platform, supporting long-term software and biopharma growth.
AI Innovation Strengthens Agilent's Growth StoryAgilent continues to expand its AI capabilities across laboratory software, automation and digital workflows. During the second quarter of fiscal 2026, AI was highlighted as a key long-term growth driver, with increasing customer adoption and continued investments in digital laboratory solutions expected to support sustainable growth. Agilent is integrating AI across its analytical instruments, laboratory informatics and automation solutions to enhance scientific workflows and operational efficiency.
Agilent is further expanding its digital laboratory capabilities through its announcement of the China Innovation Center in June 2026, which focuses on AI, automation and digital laboratory technologies to enable next-generation smart laboratories. These initiatives strengthen Agilent's AI-enabled laboratory portfolio and are expected to address growing demand for AI-powered laboratory software and automation solutions, strengthening the company's long-term growth prospects.
Agilent Provides Strong Fiscal Q3 2026 OutlookAgilent's improving demand environment, expanding AI software portfolio and continued product innovation are expected to benefit the company’s top-line growth.
For the third quarter of fiscal 2026, A expects revenues to be in the range of $1.83-$1.85 billion, implying 5.0%-6.5% reported growth and 4.4%-5.9% core growth.
The Zacks Consensus Estimate for third-quarter fiscal 2026 revenues is pegged at $1.84 billion, indicating year-over-year growth of approximately 6.02%.
The consensus estimate for third-quarter fiscal 2026 earnings is pegged at $1.47 per share, which has decreased by a penny over the past 30 days, indicating year-over-year growth of 7.30%.
A’s Zacks Rank & Stocks to ConsiderCurrently, Agilent carries a Zacks Rank #3 (Hold).
Fortrea Holdings Inc (FTRE - Free Report) , Neurocrine Biosciences (NBIX - Free Report) and PTC Therapeutics (PTCT - Free Report) are some better-ranked stocks that investors can consider in the broader Zacks Medical sector. Fortrea Holdings Inc, Neurocrine Biosciences and PTC Therapeutics sport a Zacks Rank #1 (Strong Buy) each at present. You can see the complete list of today’s Zacks #1 Rank stocks here.
FTRE shares have lost 1.4% in the year-to-date period. The long-term earnings growth rate for Fortrea Holdings is pegged at 40.91%.
NBIX shares have risen 25.6% in the year-to-date period. The long-term earnings growth rate for Neurocrine Biosciences is pegged at 33.41%.
Shares of PTCT have gained 16.6% in the year-to-date period. The long-term earnings growth rate for PTC Therapeutics is pegged at 27.74%.
United Therapeutics oznámila pozitivní výsledky fáze III pro Tyvaso u IPF, což podporuje plánované podání doplňkové žádosti u FDA. Firma zároveň cílí na roční tržby ve výši 4 miliard USD do konce roku 2027.
Key Takeaways UTHR reported positive phase III results for Tyvaso in IPF, supporting a planned FDA supplemental filing.UTHR plans an FDA filing for ralinepag after phase III success & targets $4B annual revenue run rate by 2027.UTHR is advancing organ manufacturing while facing growing competition for its core PAH therapies. Shares of United Therapeutics (UTHR - Free Report) have gained 14% year to date against the industry’s 0.8% decline, driven by major clinical breakthroughs and improved long-term growth visibility that have significantly strengthened investor confidence.
Image Source: Zacks Investment Research
UTHR’s Meaningful Pipeline Expansion Encourages InvestorsInvestor sentiment has been boosted by encouraging progress across United Therapeutics' pipeline.
The company is expanding nebulized Tyvaso beyond its approved pulmonary arterial hypertension (PAH) and pulmonary hypertension associated with interstitial lung disease (PH-ILD) indications into larger pulmonary fibrosis markets such as idiopathic pulmonary fibrosis (IPF) and progressive pulmonary fibrosis (PPF). The company's IPF development program consists of two pivotal phase III studies, TETON-1 and TETON-2. The studies share a similar design, differing primarily in their geographic scope. TETON-1 was conducted at sites across the United States and Canada, while TETON-2 enrolled patients at sites outside these countries.
In March 2026, the company announced positive results from the late-stage TETON-1 study, which achieved its primary endpoint by demonstrating a statistically significant improvement in lung function for patients with IPF. The magnitude of benefit observed in TETON-1 exceeded the already strong outcomes previously reported in TETON-2, representing a significant advancement for patients with IPF.
Positive phase III data from both the TETON-1 and TETON-2 studies support a planned FDA supplemental application for Tyvaso in IPF. Management believes the IPF opportunity alone could eventually surpass Tyvaso's current PAH revenues. It is also enrolling patients in the phase III TETON PPF study evaluating the drug in patients with PPF.
The company's late-stage PAH candidate ralinepag delivered positive phase III data from the ADVANCE OUTCOMES study in March. The study met its primary and secondary endpoints. UTHR intends to submit a new drug application for ralinepag to the FDA in the second half of 2026.
The company is developing an inhaled dry-powder version of ralinepag (RAL-DPI) in collaboration with MannKind Corporation. While initially targeting PAH, management sees potential opportunities for RAL-DPI in PH-ILD, IPF and PPF.
Together, Tyvaso's label expansion and the ralinepag franchise are expected to drive long-term growth, supporting the company's goal of increasing its annual revenue run rate from $3 billion to $4 billion by the end of 2027 and boosting investor sentiment.
Organ Manufacturing Business on MoveUnited Therapeutics continues to strengthen its long-term growth outlook through steady progress in its organ manufacturing platform, which spans hearts, kidneys, livers and lungs. The company is advancing multiple technologies, including xenotransplantation, regenerative medicine, bioengineered organs, 3D bioprinting and ex-vivo lung perfusion (EVLP) to address the global shortage of donor organs.
Its xenotransplantation portfolio includes development-stage candidates UKidney, UHeart and UThymoKidney. The FDA cleared the investigational new drug application for the phase I EXPRESS study evaluating UHeart in May. United Therapeutics received FDA premarket approval for LungFX, the first EVLP device for assessing donor lungs outside the body, with a commercial launch planned for 2027.
Earlier this month, the acquisition of Thymmune Therapeutics expanded the company's regenerative medicine portfolio with the preclinical thymic cell therapy THY-100, strengthening its long-term strategy to improve organ transplantation and immune restoration.
UTHR Faces Competitive PressureUnited Therapeutics generates most of its revenues from its treprostinil-based PAH therapies, including Tyvaso, Orenitram, Adcirca and Remodulin. The company markets two versions of Tyvaso: Tyvaso dry powder inhalation (DPI) and nebulized Tyvaso. The drug remains the company's biggest growth driver, with the more convenient Tyvaso DPI continuing to gain traction and posting 9% year-over-year sales growth in the first quarter of 2026.
A key concern for United Therapeutics is the increasing competitive pressure on its core PAH franchise. While Tyvaso DPI continues to grow, sales of nebulized Tyvaso have been declining due to market erosion following the loss of exclusivity in May 2025 and the FDA approval of Liquidia Corporation’s (LQDA - Free Report) Yutrepia, the first inhaled dry-powder competitor for PAH and PH-ILD. Yutrepia's rapid market adoption, with 44% sequential sales growth in the first quarter of 2026, underscores the growing competitive threat to Tyvaso products.
UTHR’s heavy reliance on the PAH market remains a risk as its established therapies face rising competition from generics and newer treatments. With limited diversification beyond PAH, United Therapeutics' long-term growth depends largely on the successful development and commercialization of its pipeline, making any clinical, regulatory or commercialization setbacks a potential headwind for the stock.
UTHR's Zacks Rank & Stocks to ConsiderUnited Therapeutics currently carries a Zacks Rank #3 (Hold).
Some better-ranked stocks in the biotech sector are Neurocrine Biosciences (NBIX - Free Report) and Amarin Corporation (AMRN - Free Report) , each currently sporting a Zacks Rank #1 (Strong Buy). You can see the complete list of today’s Zacks #1 Rank stocks here.
Over the past 60 days, estimates for Neurocrine Biosciences’ 2026 earnings per share have risen from $9.15 to $9.47. Over the same period, EPS estimates for 2027 have risen from $10.23 to $10.79. NBIX shares have lost 25.6% year to date.
Neurocrine Biosciences’ earnings beat estimates in three of the trailing four quarters and missed in the remaining one, the average surprise being 9.08%.
Over the past 60 days, loss per share estimates for Amarin Corporation have narrowed from $15.20 to 65 cents for 2026. Over the same period, estimates for loss per share have also narrowed from $13.00 to 51 cents for 2027. AMRN shares have risen 8.5% year to date.
Amarin Corporation’s earnings beat estimates in three of the trailing four quarters and missed in the remaining one, the average surprise being 50.02%.
PNC Financial po akvizici FirstBank rozšířila síť o 95 poboček a posílila depozitní i úvěrovou základnu. Banka zároveň po stress testu Fedu zvýšila čtvrtletní dividendu o 18 % na 2 USD na akcii.
Key Takeaways PNC is expanding through FirstBank and other deals, strengthening its market reach and revenue base.PNC benefits from solid capital, liquidity and an 18% dividend hike after the 2026 Fed stress test.PNC targets long-term growth through branch expansion, though expenses and commercial loans remain risks. The PNC Financial Services Group, Inc. (PNC - Free Report) shares have gained 14.3% in the past six months, outperforming the industry’s growth of 7.2%. Its close peers, Citigroup Inc. (C - Free Report) , have gained 16.7%, whereas shares of Wells Fargo (WFC - Free Report) have lost 9.9% during the same time period.
Price Performance
Image Source: Zacks Investment Research
Can PNC shares continue gaining after their recent strength? Let’s take a closer look.
What’s Aiding PNC’s Performance?Business Expansion Through Strategic Acquisitions: PNC Financial has been actively expanding its business through strategic acquisitions and partnerships to strengthen its market presence and diversify its revenue base. In January 2026, the company acquired FirstBank Holding Company, substantially expanding its franchise in Colorado and Arizona. The acquisition added 95 branches and $26.8 billion in assets, with management expecting the deal to contribute nearly $1 per share to earnings by 2027. Further, the successful conversion of 780,000 FirstBank customers, more than 1,620 employees and all 95 branches in June 2026 marked the completion of a major integration milestone.
Beyond expanding its banking footprint, PNC Financial has continued to enhance its product offerings and investment banking capabilities. In August 2025, it acquired Aqueduct Capital Group to strengthen the fund placement capabilities of Harris Williams. In 2024, the company partnered with Plaid to facilitate secure customer data sharing and expanded its alliance with TCW Group to offer private credit solutions to middle-market companies. These strategic initiatives are expected to support revenue diversification and drive long-term growth.
Solid Liquidity and Capital Strength Drive Shareholder Value: The company maintains a solid liquidity and capital position. As of March 31, 2026, its total available liquidity (comprising cash and due from banks, and interest-earning deposits in banks) was $31.7 billion, while long-term debt totaled $63.9 billion, with no short-term borrowings. Further, in June 2026, PNC cleared the Federal Reserve’s 2026 stress test, with its Common Equity Tier 1 (CET1) ratio of 10.1% comfortably exceeding its stress capital buffer-based regulatory requirement of 7%. Backed by this capital strength, the company raised its quarterly common stock dividend by 18% to $2 per share in July 2026.
Over the past five years, PNC has increased its dividend six times, delivering a five-year annualized dividend growth rate of 6%. Further, its current dividend yield of 2.76% compares favorably with the industry's average of 1.66%.
Dividend Yield
Image Source: Zacks Investment Research
Likewise, its peers, WFC and C, also announced plans to increase dividends following the 2026 Fed’s stress test. Wells Fargo intends to raise its third-quarter 2026 common stock dividend by 11% to 50 cents per share, subject to board approval, while Citigroup plans to increase its quarterly common stock dividend by 12% to 67 cents per share beginning in the third quarter of 2026, subject to quarterly board approval.
Apart from regular dividend hikes, PNC also returns capital through share repurchases. The company has an existing authorization to repurchase up to 100 million common shares, with nearly 32 million shares remaining under the program as of March 31, 2026. Given its strong liquidity and capital position, PNC's capital deployment initiatives appear sustainable and are expected to continue enhancing shareholder value.
Steady Growth in Loans and Deposits: The company continues to benefit from steady growth in its loan and deposit balances, supported by a strong balance sheet and strategic expansion initiatives. Its total loans and deposits recorded a compound annual growth rate (CAGR) of 5.5% and 7.3%, respectively, between 2019 and 2025. The growth momentum continued in the first quarter of 2026, with both loan and deposit balances increasing year over year. The acquisition of FirstBank further strengthened the company's balance sheet, adding nearly $16 billion in loans and $23 billion in deposits during the quarter. Earlier, in 2023, PNC Financial acquired approximately $16 billion of loan commitments from Signature Bank, enhancing its lending capacity.
Looking ahead, a well-diversified deposit base, continued growth in commercial and operational deposits and a relatively favorable interest rate environment are expected to support loan demand. Reflecting these tailwinds, management expects average loan balances to grow nearly 11% year over year in 2026, up from its earlier expectation of about 8% growth.
Expansion of Branch Network: PNC Financial continues to invest in its retail banking franchise through an aggressive branch expansion strategy. In November 2025, the company increased its planned investment in branch expansion to nearly $2 billion from the $1.5 billion announced in 2024. The initiative includes opening more than 300 branches across nearly 20 U.S. markets, renovating its entire branch network by 2029 and hiring more than 2,000 employees by 2030.
The company's focus on expanding in high-growth markets has already supported customer acquisition and checking account growth. Going forward, the expanded branch network is expected to strengthen PNC Financial's retail banking presence, deepen customer relationships and support sustainable revenue growth.
Few Concerns Prevail for PNCPersistent Expense Pressure: PNC Financial continues to witness an increase in operating expenses. The company's non-interest expenses recorded a CAGR of 4.6% between 2019 and 2025, with the upward trend continuing in the first quarter of 2026. While the company exceeded its 2025 Continuous Improvement Program cost-saving target, merger integration costs and continued investments in technology, branch expansion and personnel are expected to keep expenses elevated in the near term.
Total Expense Trend
Image Source: Zacks Investment Research
Loan Portfolio Concentration: The company's loan portfolio remains heavily concentrated in commercial lending. As of March 31, 2026, commercial loans accounted for 70% of total loans. Despite a diversified commercial portfolio, persistent weakness in office real estate and an uncertain macroeconomic environment remain concerns. Commercial loans accounted for 61.5% of total non-performing loans and 47.4% of net charge-offs as of March 31, 2026. Further, management expects commercial real estate charge-offs, particularly in the office segment, to remain elevated, posing risks to asset quality if economic conditions weaken.
Parting Thoughts on PNCPNC Financial's strategic acquisitions, expanding branch network, steady loan and deposit growth and solid liquidity position are expected to support its long-term financial performance.
Over the past week, the Zacks Consensus Estimate for 2026 earnings per share has been revised upward, while the estimate for 2027 has been revised downward.
Estimate Revision Trend
Image Source: Zacks Investment Research
The expected estimates imply growth of 13.5% and 11.4% for 2026 and 2027, respectively.
However, persistent expense pressure and the company's significant exposure to commercial lending remain key near-term headwinds. Additionally, the Fed's signal of a possible rate hike later in 2026 might put additional pressure on asset quality.
From a valuation perspective, PNC stock appears inexpensive relative to the industry. It is currently trading at a forward 12-month price-to-earnings (P/E) multiple of 12.36X, below the industry's 14.67X. Meanwhile, Wells Fargo and Citigroup trade at P/E multiples of 11.51X and 11.73X, respectively.
Price-to-Earnings F12 M
Image Source: Zacks Investment Research
Investors already holding the stock may consider retaining their positions, given PNC Financial's diversified growth initiatives, solid liquidity profile and sustainable capital deployment strategy. Those considering fresh investments may prefer to wait for a more favorable entry point until there is greater clarity on expense trends and commercial credit quality.
Currently, PNC Financial carries a Zacks Rank #3 (Hold). You can see the complete list of today's Zacks #1 Rank (Strong Buy) stocks here.
GE HealthCare spolupracuje s Mayo Clinic na studii MI-BET, která má pomocí zobrazování, biomarkerů a dat přizpůsobit radioligandovou terapii pacientům s pokročilým karcinomem prostaty. Využije systém StarGuide SPECT/CT a MIM LesionID Pro k monitorování odpovědi nádoru.
Key Takeaways GE HealthCare is collaborating with Mayo Clinic to advance personalized cancer theranostics.The MI-BET study will assess whether imaging, biomarkers and data can tailor RLT cycles.Researchers will use StarGuide SPECT/CT and MIM LesionID Pro to monitor tumor response. GE HealthCare (GEHC - Free Report) has announced a new research collaboration with Mayo Clinic to advance personalized cancer treatment through the MI-BET (Molecular Imaging Biomarker-Based End of Therapy Trial) study. The initiative will evaluate whether imaging, blood-based biomarkers and clinical data can help tailor radioligand therapy for patients with advanced prostate cancer, supporting more adaptive treatment decisions and expanding the use of theranostics.
From an investor's perspective, the collaboration reinforces GE HealthCare's growing focus on precision oncology and theranostics, a rapidly evolving area of cancer care. By leveraging its StarGuide SPECT/CT platform and MIM Software's advanced imaging capabilities in a high-profile clinical research setting, the company stands to strengthen the clinical validation and long-term adoption of its imaging technologies. If the study generates favorable evidence, it could enhance GE HealthCare's competitive positioning in molecular imaging, support future demand for its theranostics portfolio and create additional growth opportunities in the expanding precision medicine market.
Likely Trend of GEHC Stock Following the NewsShares of GEHC have traded flat since the announcement on July 8. In the year-to-date period, shares of the company have lost 21.2% compared with the industry’s 20.4% decline. The S&P 500 increased 9.9% in the same time frame.
In the long term, the collaboration is expected to strengthen GE HealthCare's position in the fast-growing theranostics and precision oncology markets by generating real-world clinical evidence for its advanced molecular imaging technologies. Positive findings from the MI-BET study could accelerate the adoption of the company's StarGuide SPECT/CT platform and MIM Software solutions across healthcare systems, while reinforcing GE HealthCare's role as a strategic partner in data-driven cancer care.
The collaboration also enhances the company's innovation pipeline, supports the development of imaging biomarkers and adaptive treatment workflows and could create opportunities for broader commercial adoption as theranostics becomes an increasingly important component of personalized oncology.
GEHC currently has a market capitalization of $29.52 billion.
Image Source: Zacks Investment Research
More on the NewsThe MI-BET study is designed to challenge the conventional approach of administering a fixed number of radioligand therapy cycles by evaluating whether treatment can instead be tailored to an individual patient's response. Using GE HealthCare's StarGuide SPECT/CT system alongside MIM Software's MIM LesionID Pro, researchers will monitor tumor response throughout treatment.
By integrating imaging findings with clinical outcomes and blood-based biomarkers, the study aims to determine whether these data-driven insights can guide decisions such as pausing or adapting therapy based on disease progression. Researchers also intend to identify predictive biomarkers that could help physicians anticipate patient response earlier in the treatment journey, enabling more personalized care.
The collaboration is also focused on expanding access to advanced theranostics by encouraging broader patient participation through community outreach, partnerships with advocacy organizations and the use of telemedicine to reduce barriers to enrollment. According to Mayo Clinic, the initiative reflects a broader shift toward adaptive, patient-specific cancer care models that seek to optimize treatment effectiveness while minimizing unnecessary therapy. In addition to evaluating treatment duration, the study will investigate novel imaging biomarkers and data-driven approaches that could further enhance clinical decision-making and improve patient outcomes.
The research will be conducted at Mayo Clinic's Rochester, MN, campus, combining the organization’s expertise in clinical practice, research and product development. As part of the collaboration, Mayo Clinic has also become the first U.S. site to investigate GE HealthCare's next-generation StarGuide GX SPECT/CT technology, which is designed to improve tumor assessment precision while potentially reducing scan times. Although the StarGuide GX system has received CE Mark certification and is not yet approved for commercial sale in the United States, the collaboration underscores GE HealthCare's commitment to advancing next-generation molecular imaging technologies and supporting the broader adoption of precision oncology solutions.
Favorable Industry Prospect for GEHCGoing by the data provided by Precedence Research, the global theranostics market size was calculated at $10.29 billion in 2025 and is predicted to increase from $11.50 billion in 2026 to approximately $31.38 billion by 2035, expanding at a CAGR of 11.8%.
The market growth is driven by the rising incidence of chronic diseases, the shift toward personalized medicine, and advances in molecular imaging and radiopharmaceuticals.
A Recent Development by GEHCRecently, GEHC announced the Allia platform upgrade pathways to help healthcare providers modernize select legacy Innova and Discovery Image Guiding Solutions systems. The initiative comes as healthcare providers face growing procedural complexity, rising patient volumes and aging imaging equipment.
The upgrades enable health systems to access the latest Allia technologies and AI-enabled workflows while preserving existing infrastructure, reducing the need for major construction and minimizing disruption to clinical operations.
Some better-ranked stocks from the broader medical space are Globus Medical (GMED - Free Report) , West Pharmaceutical (WST - Free Report) and Intuitive Surgical (ISRG - Free Report) .
Globus Medical, currently carrying a Zacks Rank #2 (Buy), reported a first-quarter 2026 adjusted earnings per share (EPS) of $1.12, which surpassed the Zacks Consensus Estimate by 22.1%. Revenues of $759.9 million beat the Zacks Consensus Estimate by 4.0%. You can see the complete list of today’s Zacks #1 Rank (Strong Buy) stocks here.
GMED has an estimated long-term earnings growth rate of 10.2% compared with the industry’s 12.6% growth. The company’s earnings beat estimates in each of the trailing four quarters, the average surprise being 26.3%.
West Pharmaceutical, currently flaunting a Zacks Rank #1, reported first-quarter 2026 EPS of $2.13, which beat the Zacks Consensus Estimate by 26.8%. Revenues of $844.9 million surpassed the Zacks Consensus Estimate by 8.5%.
WST has an estimated long-term earnings growth rate of 13.9% compared with the industry’s 9.5% growth. The company’s earnings surpassed estimates in each of the trailing four quarters, the average surprise being 19.4%.
Intuitive Surgical, carrying a Zacks Rank #2 at present, reported first-quarter 2026 adjusted EPS of $2.50, which beat the Zacks Consensus Estimate by 20.2%. Revenues of $2.77 billion surpassed the Zacks Consensus Estimate by 6.2%.
ISRG has a long-term estimated growth rate of 14.6% compared with the industry’s 12.6% growth. The company’s earnings surpassed estimates in each of the trailing four quarters, the average surprise being 16.8%.
Bank of America uvedla, že plánovaná akvizice Synaptics společností Onsemi může přinést dlouhodobé synergie a posílit její portfolio edge AI. Akcie Onsemi ve čtvrtek odpoledne stouply o více než 5 %.
Onsemi (NASDAQ:ON)'s proposed acquisition of Synaptics could create long-term strategic benefits, with Bank of America writing that a meeting with management increased its confidence in the rationale and potential synergies of the transaction.
The analysts wrote that Synaptics adds highly complementary compute assets to Onsemi (NASDAQ:ON)’s existing strengths in power, sensing and control, supporting the company’s ambition to build a complete edge AI portfolio.
They wrote that acquiring these capabilities through M&A allows Onsemi to accelerate time to market while avoiding the distraction of developing them internally.
Bank of America wrote that the market underappreciates the potential long-term benefits of the transaction, noting that initial cost synergy assumptions of $200 million could underestimate the ultimate savings potential. The analysts added that revenue synergies could also be significant over time as Onsemi cross-sells Synaptics products through its distribution channel.
The analysts wrote that the all-stock transaction preserves Onsemi’s balance sheet flexibility to fund buybacks and invest in new products, including Synaptics’ Astra program. They added that the deal could provide solid EPS accretion above the $7 in long-term EPS power they see for core Onsemi.
Bank of America also highlighted an expanded market opportunity, writing that Onsemi now believes the total addressable market for its core business exceeds $200 billion, compared with $64 billion at its previous analyst day, while Synaptics adds an additional $30 billion.
The analysts wrote that Synaptics’ consumer and enterprise PC exposure could be viewed negatively by investors but noted that these businesses generate gross margins in the high-50% range, above Onsemi’s typical high-40% gross margins.
On artificial intelligence opportunities, Bank of America wrote that Onsemi’s AI data center business is on track to at least double in 2026 from $250 million in 2025. The analysts highlighted the company’s vertical gallium nitride technology, writing that it is differentiated as the only device supporting high frequency and high voltages in a single chip.
The analysts wrote that Onsemi’s core initiatives remain on track, including progress in automotive silicon carbide for China electric vehicles, ethernet and zonal architecture, while industrial segments are recovering as purchasing managers’ indexes move above 50. They also noted that the recent exit of two facilities represents 50 basis points of a targeted 200 basis points of gross margin expansion from Onsemi’s fab restructuring initiatives.
Bank of America maintained its ‘Buy’ rating, writing that Onsemi’s upcoming analyst day could serve as a catalyst.
Shares of Onsemi traded up more than 5% on Thursday afternoon amid a broader rally in chipmaker stocks.
Denali Therapeutics oznámila, že spoluzakladatel a generální ředitel Ryan Watts, Ph.D., vystoupí s úvodním plenárním projevem na Alzheimer’s Association International Conference (AAIC) 2026, která se uskuteční 12.–15. července v Londýně. Firma zároveň představí své kandidáty na léčbu Alzheimerovy choroby DNL628 a DNL921.
July 09, 2026 16:01 ET | Source: Denali Therapeutics Inc.
Denali co-founder and CEO Ryan Watts, Ph.D., to deliver opening plenary address at 2026 AAIC in London on July 12, 2026
Presentation will highlight recent scientific advances and future opportunities to accelerate discovery and development of medicines for neurodegenerative diseases
Denali is advancing multiple investigational therapies designed to cross blood-brain barrier for Alzheimer’s disease, including DNL628 (OTV:MAPT) targeting tau and DNL921 (ATV:Abeta) targeting amyloid beta
SOUTH SAN FRANCISCO, Calif., July 09, 2026 (GLOBE NEWSWIRE) -- Denali Therapeutics Inc. (Nasdaq: DNLI) today announced that co-founder and Chief Executive Officer Ryan Watts, Ph.D., will deliver the opening plenary address, titled “Accelerating the Discovery and Development of Medicines for Neurodegeneration,” at the Alzheimer’s Association International Conference® (AAIC), taking place July 12-15 in London. Dr. Watts will discuss recent scientific advances and future opportunities including new insights in the biology of disease, the use of biomarkers for diagnosis and assessment of treatment effect, and the potential for therapeutics to cross the blood-brain barrier for enhanced delivery to the brain.
“We are entering a new era of drug development for Alzheimer’s disease, driven by significant developments in biology, biomarkers and the blood-brain barrier, which has been a major hurdle for the treatment of neurodegenerative disease,” said Dr. Watts. “At Denali, our work has focused on solving the challenge of brain delivery so that people living with neurologic diseases such as Alzheimer’s can benefit from the power of biotherapeutics. We are excited to be part of the community working to transform the lives of millions of individuals and families worldwide by applying these scientific breakthroughs to deliver the next generation of therapies for Alzheimer’s disease.”
Denali Therapeutics has developed and clinically validated the TransportVehicle™, a proprietary technology designed to effectively deliver biologic therapeutics such as antibodies, enzymes and oligonucleotides across the blood-brain barrier by leveraging the body’s natural iron transport system (the transferrin receptor). In March 2026, Denali received accelerated approval from the U.S. Food and Drug Administration for the first and only FDA-approved biologic specifically designed to cross the blood-brain barrier: AVLAYAH™ (tividenofusp alfa-eknm), an enzyme replacement therapy for the treatment of neurologic manifestations of Hunter syndrome (mucopolysaccharidosis type II) when initiated in presymptomatic or symptomatic pediatric patients weighing at least 5 kg prior to advanced neurologic impairment.
Denali is developing a broad portfolio of investigational, TransportVehicle-enabled therapeutic candidates including DNL628 (OTV:MAPT) and DNL921 (ATV:Abeta) targeting tau and amyloid beta, respectively, the two hallmark pathologies of Alzheimer’s disease.
DNL628 (OTV:MAPT) is enabled by the Oligonucleotide TransportVehicle™ (OTV) and is designed to target the MAPT gene that encodes for tau, which has been shown to be closely associated with cognitive decline. Preclinical research (link) demonstrated that the OTV achieved broad and uniform central nervous system distribution of antisense oligonucleotides, including deeper brain structures, following intravenous administration as compared to intrathecally delivered therapy.1 The first patients in Denali’s Phase 1b clinical study of DNL628 were dosed in the first half of 2026, and Denali expects clinical safety and biomarker proof-of-concept data from the study in 2027.
DNL921 (ATV:Abeta) is enabled by the Antibody TransportVehicle™ (ATV) and is designed to reduce amyloid plaques. In preclinical research published in the journal Science (link), Denali demonstrated improved brain distribution of ATV:Abeta and reduced risk of swelling and small bleeds in the brain – effects collectively known as amyloid-related imaging abnormalities (ARIA) – compared to conventional antibody treatment. The findings suggest that TransportVehicle-enabled brain delivery of immunotherapy bypasses amyloid-laden large vessels by traveling through smaller capillaries, offering a potential strategy to mitigate ARIA risk seen with first-generation anti-amyloid therapies.2 Denali submitted a Clinical Trial Application (CTA) for DNL921 in the first half of 2026 and, pending regulatory approval of the CTA, expects to initiate a Phase 1/1b clinical trial, with potential for clinical safety and biomarker proof-of-concept data in 2027.
About the Denali TransportVehicle™ Platform
The blood-brain barrier (BBB) is essential in maintaining the brain’s microenvironment and protecting it from harmful substances and pathogens circulating in the bloodstream. Historically, the BBB has posed significant challenges to drug development for central nervous system diseases by preventing most drugs from reaching the brain in therapeutically relevant concentrations. Denali’s TransportVehicle™ (TV) platform is a proprietary technology designed to effectively deliver large therapeutic molecules such as antibodies, enzymes and oligonucleotides throughout the whole body, including the brain, by crossing the BBB after intravenous administration. The TV platform is based on engineered Fc domains that bind to specific natural transport receptors, such as transferrin receptor and CD98 heavy chain amino acid transporter, which are expressed at the BBB and deliver the TV and its therapeutic cargo to the brain through receptor-mediated transcytosis. In animal models, antibodies and enzymes engineered with the TV platform demonstrate more than 10- to 30-fold greater brain exposure than similar antibodies and enzymes without this technology. Oligonucleotides engineered with the TV platform demonstrate more than a 1,000-fold greater brain exposure in primates than systemically delivered oligonucleotides without this technology. Improved exposure and broad distribution in the brain may increase therapeutic efficacy by enabling widespread achievement of therapeutically relevant concentrations of product candidates. The TV platform has been clinically validated, with AVLAYAH™ (tividenofusp alfa-eknm) as the first FDA-approved medicine leveraging transferrin receptor to cross the BBB.
About Denali Therapeutics
Denali Therapeutics Inc. is a biotechnology company pioneering a new class of biotherapeutics designed to cross the blood-brain barrier (BBB) using its proprietary TransportVehicle™ platform. With the first FDA-approved biologic specifically designed to cross the BBB, a clinically validated delivery platform and a growing portfolio of therapeutic candidates across all stages of development, Denali is advancing toward its goal of delivering effective medicines to transform life for people with neurodegenerative diseases, lysosomal storage disorders and other serious diseases. For more information, please visit www.denalitherapeutics.com.
Forward-Looking Statements
This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Forward-looking statements expressed or implied in this press release include, but are not limited to, statements by Denali’s Chief Executive Officer; statements regarding expectations for Denali’s TransportVehicle™ (TV) platform and its therapeutic and commercial potential; including the potential to deliver enzymes and the Enzyme TransportVehicle™ (ETV) franchise, antibodies and the Antibody TransportVehicle™ (ATV) franchise, and oligonucleotides and the Oligonucleotide TransportVehicle™ (OTV) franchise; statements regarding plans, timelines and expectations related to AVLAYAH™ (tividenofusp alfa-eknm); statements regarding plans, timelines and expectations related to the DNL628 clinical development program, including the ongoing Phase 1 study and timing of data readouts; and statements regarding plans, timelines and expectations related to the DNL921 clinical development program, including the planned Phase 1 study, the potential to mitigate amyloid-related imaging abnormalities (ARIA) and the timing of data readouts. Actual results may differ materially from those expressed or implied by these forward-looking statements due to a variety of risks and uncertainties. These include, but are not limited to, uncertainties related to the FDA’s policies and accelerated approval program; risks arising from adverse economic conditions and their impact on Denali’s business and operations; the possibility of events or changes that could lead to the termination of Denali’s collaboration agreements; challenges associated with Denali’s transition to a commercial company; the ability of Denali and its collaborators to complete the development and, if approved, the commercialization of product candidates; difficulties in patient enrollment for ongoing and future clinical trials; whether the current ongoing trials have been powered sufficiently to demonstrate approvability to regulatory agencies; reliance on third-party manufacturers and suppliers for clinical trial materials; dependence on the successful development of Denali’s blood-brain barrier platform technology and related programs; potential delays or failures in meeting expected clinical trial timelines; the risk that promising preclinical profiles may not be replicated in clinical settings; discrepancies between preclinical, early-stage or preliminary clinical results and outcomes from later-stage trials; the occurrence of significant adverse events or other undesirable side effects; the uncertainty surrounding regulatory approvals required for commercialization in the U.S., Europe or other international jurisdictions; Denali’s ability to advance a pipeline of product candidates or develop commercially successful products; developments relating to Denali's competitors and its industry, including competing product candidates and therapies; Denali’s ability to obtain, maintain or protect intellectual property rights related to its product candidates; the implementation and success of Denali’s strategic plans for its business, product candidates and blood-brain barrier platform technology; Denali's ability to obtain additional capital to finance its operations, as needed; Denali's ability to accurately forecast future financial results in the current environment; and other risks and uncertainties, including those described in Denali's most recent Annual and Quarterly Reports on Forms 10-K and 10-Q filed with the Securities and Exchange Commission (SEC) on February 26, 2026 and May 7, 2026, respectively, and Denali’s future reports to be filed with the SEC. Except for AVLAYAH, Denali's product candidates are investigational, and their safety and efficacy profiles have not yet been established. Denali does not undertake any obligation to update or revise any forward-looking statements, to conform these statements to actual results or to make changes in Denali’s expectations, except as required by law.
References
Barker SJ, Thayer MB, Kim S, et al. Targeting the transferrin receptor to transport anti-sense oligonucleotides across the mammalian blood-brain barrier. Sci Transl Med 2024 Aug 14;16(760).Pizzo ME, Plowey ED, Khoury N, et al. Transferrin receptor-targeted anti-amyloid antibody enhances brain delivery and mitigates ARIA. Science 2025 Aug 7;389(6760).
Investor Contact:
Laura Hansen [email protected]
Massive dividend yields are a huge draw for investors – both because everyone likes income…and because a company that can pay a dividend surely has the cash to pay out that dividend, right?
Most of the time, that’s true. But things can get rough when a company doesn’t have the cash to continue funding the dividend. One of your early signs is an especially high yield – in general, anything over 5% or 6% is worth digging into further. A yield that high may be a signal that the market is losing confidence in the business (and in its ability to continue funding the dividend). There are, of course, exceptions, but it’s a good initial rule of thumb.
It’s also worth understanding how much of a company’s earnings or cashflow are eaten up by the dividend.
For BDCs, the right coverage test is net investment income (NII) per share versus the dividend (GAAP EPS whipsaws on mark-to-market losses and distorts the picture). When NII stops covering the payout, when NAV per share slides, and when supplemental distributions quietly disappear, the payout is stretched. Here are five 10%+ yielders where those warning signs are lit.
Saratoga Investment Corp. (SAR) Saratoga Investment (NYSE:SAR) advertises a 14.0% annualized yield on its $0.25 monthly base dividend. Shares have since slid to $17.98, inflating the yield further.
The coverage math is the red flag. Q1 FY27 adjusted NII came in at $0.47 per share against a $0.75 quarterly dividend, a coverage ratio of just 0.63x, and NII has stepped down from $0.53 the prior quarter. Saratoga’s own filing flagged a FY26 payout ratio of 122.95%. NAV per share fell 4.9% sequentially to $23.23 on $15.2 million in net markdowns, and financing costs jumped after a $175 million bond at 4.375% was replaced with debt at 7.25% and 7.50%.
The bull case: $196.8 million of undrawn borrowing capacity and low non-accruals at 0.2% of fair value. But with NII covering less than two-thirds of the payout, the monthly $0.25 base looks stretched.
FS KKR Capital Corp. (FSK) FS KKR Capital (NYSE:FSK | FSK Price Prediction) is already mid-cut, and the numbers suggest the second reduction may not be the last. Shares are down 41.24% over the past year to $10.56.
The Q2 2026 distribution was stepped down to $0.42 from $0.48, following an earlier reduction from $0.70. Yet Q1 2026 adjusted EPS of $0.41 missed the $0.4433 consensus by 7.51% and barely covers even the new payout. NAV per share dropped to $18.83 from $20.89, non-accruals climbed to 4.2% at fair value (8.1% at cost), and net leverage spiked to 131%.
Act now: the analyst who called NVIDIA in 2010 just named his top 10 AI stocks — and Blue Owl Technology Finance didn't make the cut. Grab the names FREE today.
The KKR rescue package ($150 million preferred equity injection, $150 million tender at $11, a $300 million buyback, and a 50% incentive fee waiver for four quarters) is a lifeline that buys time without curing the underlying earnings gap. Securities class action lawsuits alleging overstated dividend durability tell you what the market thinks.
BlackRock TCP Capital Corp. (TCPC) BlackRock TCP Capital (NASDAQ:TCPC) has already cut once and still looks fragile. The quarterly dividend was reduced to $0.17 from $0.25 for Q1 2026, and shares have fallen 50.44% over the past year to $3.18, keeping the yield above 20%.
NII of $0.22 covers the new $0.17 dividend, but the cushion is thin and the trend is ugly. NAV per share collapsed 19% in Q4 2025 to $7.07 and slipped another 4.9% to $6.72 in Q1 2026. Thirteen portfolio companies sit on non-accrual, representing 7.6% at cost, and portfolio yield compression is severe: new investments are being originated at 8.1% while exits ran off at 11.2%. With management prioritizing exits over new deployments, forward NII faces further pressure.
Blue Owl Technology Finance Corp. (OTF) Blue Owl Technology Finance (NYSE:OTF) is the softer warning on this list, but the setup is classic price-driven yield inflation. Shares have dropped 24.32% year-to-date to $10.15, pushing the trailing yield well into double digits.
Q1 2026 adjusted NII of $0.29 beat the $0.25 estimate, but NII has slid for four straight quarters from $0.36 in Q2 2025 to $0.29 today, while the $0.40 payout ($0.35 base plus $0.05 special) has held. Crucially, that $0.05 special is part of a five-quarter series tied to the June 2025 listing. When it rolls off, the run-rate payout drops to $1.40. Add $494.28 million in unrealized losses, NAV down to $16.49 from $17.33, and new commitment spreads compressed to 4.6% from 5.2%, and the picture is a fading tailwind.
Blue Owl Capital Corp. (OBDC) Blue Owl Capital (NYSE:OBDC) already trimmed its base dividend and left itself no cushion. The Q2 2026 payout was cut to $0.31 from $0.37, described by management as an alignment with “go-forward earnings power amid declining base rates and spread compression.”
Q1 2026 adjusted EPS of $0.31 missed the $0.35 consensus by 10.74% and now exactly matches the new dividend, meaning zero coverage cushion. Total investment income of $396.77 million fell 11.4% sequentially, and the portfolio shrank to $15.34 billion from $16.47 billion as repayments outpaced deployments. On the other side of the ledger, Moody’s upgraded OBDC to Baa2 in January 2026, leverage improved to 1.13x, and management points to roughly $4 billion of liquidity. But 1.0x NII coverage leaves no margin for another bad quarter.
The Bottom Line Across all five names, the pattern is the same: NII squeezed by falling short-term rates, spreads compressing on new deals, and NAV grinding lower. A yield only counts if the payout survives. When a cut lands, the share price usually goes with it, and the “income” disappears in both directions at once. Yield alone has never been a buy thesis; in today’s BDC market, it may be the fastest way to walk into a trap.
Act now: the analyst who called NVIDIA in 2010 just named his top 10 AI stocks — and Blue Owl Technology Finance didn't make the cut. Grab the names FREE today.
Primoris Services oznámila další problémy a překročení nákladů v projektech obnovitelných zdrojů, což poslalo akcie v intradenním obchodování dolů o 40 %. Současně nečekaně odešel provozní ředitel.
SAN FRANCISCO, July 09, 2026 (GLOBE NEWSWIRE) -- Primoris Services Corporation (NYSE: PRIM) shares cratered again during intraday trading on June 23, 2026 (-$43.34, -40%), on the company’s disclosure of additional challenges to- and cost overruns within- its renewables business projects and the abrupt departure of its Chief Operating Officer.
The news follows Primoris’ May 5, 2026 disclosure that it suffered huge year-over-year and sequential declines in revenues and gross profits for its Energy segment and identified ongoing, expanded issues with its renewables business, news which sent the price of company shares tumbling $101.69 (-50%).
Hagens Berman is actively investigating whether Primoris’ pre-May 5 statements about trends in- and operational performance of- its renewables business misled investors and, if so, whether the company violated the federal securities laws.
The firm encourages Primoris investors who suffered substantial losses to submit your losses now. The firm also encourages persons with knowledge who may be able to assist the investigation to contact its attorneys.
Visit: www.hbsslaw.com/investor-fraud/prim
Contact the Firm Now: [email protected] | 844-916-0895
Primoris’ renewable business is part of the company’s core Energy segment and historically has contributed roughly 40% of Primoris’ entire annual revenue.
After the markets closed on June 22, 2026, Primoris shocked investors when it announced that “[a]dditional challenges and cost overruns were identified as a result of continued progress on projects in the Company’s Renewables business.” Importantly, as a result of ongoing problems in six projects and additional challenges, Primoris said its 2026 renewables business revenues would decline 30% ($900 million) from the $3 billion revenues reported for 2025.
This news follows two previous disclosures about Primoris’ renewables business problems, one downplaying and the next partially indicating problems in the business.
First, in February 2026, Primoris management attributed lower gross margins to “unexpectedly higher costs” at certain renewables projects, citing difficult soil and rock conditions that required additional labor and equipment. While management later downplayed the issue as being isolated to a single project—expressing confidence in their remedial measures—they simultaneously touted the company’s ability to “accelerate project timelines” for 2026.
Second, on May 5, 2026, the market’s confidence in Primoris’s remedial measures was shattered when the company released its Q1 2026 financial results and revealed a staggering decline in the core Energy segment, with year-over-year revenues falling by $152.9 million (13.8%) and gross profits plunging by nearly 40%.
CEO Koti Vadlamudi admitted the next day during the May 6 earnings call that Primoris’s financial results were battered by cost pressures across multiple solar projects. Moving beyond the “rock and soil” reason used just months prior, Vadlamudi cited a litany of execution-related factors as the cause of the margin collapse:
Project Redesigns: Costly changes to existing plans.Labor Issues: Inability to manage specific workforce demands.Sequencing Errors: Failures in project management and timing.Weather Disruptions: Further complicating already delayed timelines Together, the May 5 and June 22, 2026 disclosures wiped out over $7.8 billion of Primoris’ market capitalization.
“We’re focused on when Primoris’ management learned of the full scope of the company’s renewables problems, including the apparent inadequacy of remediation measures,” said Reed Kathrein, the Hagens Berman partner leading the firm’s investigation.
If you invested in Primoris and have substantial losses, or have knowledge that will assist the firm’s investigation, submit your losses now.
If you’d like more information and answers to other frequently asked questions about the firm’s Primoris investigation, read more.
Whistleblowers: Persons with non-public information regarding Primoris should consider their options to help in the investigation or take advantage of the SEC Whistleblower program. Under the new program, whistleblowers who provide original information may receive rewards totaling up to 30 percent of any successful recovery made by the SEC. For more information, call Reed Kathrein at 844-916-0895 or email [email protected].
About Hagens Berman
Hagens Berman is a global plaintiffs’ rights complex litigation firm focusing on corporate accountability. The firm is home to a robust practice and represents investors as well as whistleblowers, workers, consumers and others in cases achieving real results for those harmed by corporate negligence and other wrongdoings. Hagens Berman’s team has secured more than $2.9 billion in this area of law. More about the firm and its successes can be found at hbsslaw.com. Follow the firm for updates and news at @ClassActionLaw.
Attorney Advertising. Prior results do not guarantee a similar outcome in any future case.
Teradyne v 1. čtvrtletí 2026 meziročně zvýšila tržby o 87 % na přibližně 1,3 miliardy USD, tažené poptávkou po datových centrech s AI. Poptávka související s AI tvořila téměř 70 % tržeb.
Key Takeaways TER benefits from AI data center demand, with Q1 2026 revenues soaring 87% year over year. TER's AI-related demand made up nearly 70% of revenues, up from about 60% in the prior quarter. TER faces competition from Advantest and Vertiv as both expand in AI and data center markets. Teradyne (TER - Free Report) is benefiting from the explosive growth in datacenter demand, particularly driven by artificial intelligence (AI) and the ongoing build-out of AI-centric infrastructure. In the first quarter of 2026, Teradyne reported revenues of approximately $1.3 billion, an 87% year-over-year increase and 18% above its previous record. This surge is directly tied to the company’s strategic focus on the ‘wafer to AI data center’ market, where AI-related demand accounted for nearly 70% of revenues, up from about 60% in the previous quarter.
The datacenter segment, especially devices that support AI workloads, has become a major source of revenue. In the auto/industrial segment, 46% of revenues came from datacenter devices in the first quarter of 2026. This marks a significant shift from past trends.
Teradyne is also seeing robust demand for memory test solutions, especially for high-bandwidth memory and DRAM, both of which are critical for AI compute applications. The company’s recent product launches, such as the Photon 100 for silicon photonics and Omnyx for server board testing, further strengthen its position in the rapidly evolving data center market. Strategic acquisitions and joint ventures, like the MultiLane Test Products partnership and the acquisition of TestInsight, further strengthen Teradyne’s capabilities in high-speed I/O and design-to-test software.
Teradyne expects continued robust demand, especially as AI data center build-outs drive increased need for compute, networking and memory test solutions. For the second quarter of 2026, Teradyne expects revenues in the range of $1.15-$1.25 billion.
Teradyne Suffers From Stiff CompetitionTeradyne is facing stiff competition from companies such as Advantest Corporation (ATEYY - Free Report) and Vertiv (VRT - Free Report) . Both Advantest and Vertiv are also expanding their footprints in the AI and data center markets.
In June 2026, Advantest and OpenLight partnered to develop silicon photonics test solutions for high-volume manufacturing, addressing growing demand for AI and high-performance computing applications. The collaboration aims to accelerate scalable production of next-generation optical interconnects for AI data centers.
In June 2026, Vertiv announced the completion of its acquisition of ThermoKey S.p.A., a move that enhances Vertiv’s thermal management portfolio, expands its heat rejection and heat-exchange capabilities and strengthens its long-standing relationships with OEMs and system integrators serving data centers and other critical infrastructure markets worldwide.
TER’s Share Price Performance, Valuation, and EstimatesTeradyne shares have surged 81.6% in the year-to-date period, outperforming the Zacks Computer & Technology sector’s growth of 14.7% and the Zacks Electronics - Miscellaneous Products increase of 53.3%.
TER Stock Performance
Image Source: Zacks Investment Research
TER stock is trading at a premium with a forward 12-month Price/Sales of 11.01X compared with the Electronics - Miscellaneous Products industry’s 8.31X. TER has a Value Score of D.
TER Valuation
Image Source: Zacks Investment Research
The Zacks Consensus Estimate for fiscal 2026 earnings is pegged at $7.20 per share, which has increased 1.55% over the past 30 days. This suggests 81.82% year-over-year growth.
Teradyne currently carries a Zacks Rank #2 (Buy). You can see the complete list of today’s Zacks #1 (Strong Buy) Rank stocks here.
Exelixis čeká na rozhodnutí FDA o zanzalintinibu pro metastatický kolorektální karcinom do 3. prosince 2026. Akcie EXEL za tři měsíce vzrostly o 26,8 %.
Key Takeaways Exelixis awaits an FDA decision on zanzalintinib for metastatic colorectal cancer by Dec. 3, 2026.EXEL expanded zanzalintinib studies with Merck across colorectal and renal cell cancer programs.Zanzalintinib is also advancing in lung and prostate cancer studies, broadening its potential use. Shares of Exelixis, Inc. (EXEL - Free Report) have surged 26.8% in three months, outperforming the industry’s gain of 4.5%. The stock touched a high of $57.57 on July 7.
The stock has outperformed the sector and the S&P 500 Index during this time frame.
EXEL Outperforms Industry, Sector & S&P 500 Index
Image Source: Zacks Investment Research
The broader market recovery and investors' optimism about the company's pipeline momentum are most likely contributing to the rally, notwithstanding the recent pipeline setback. In such a scenario, a deeper assessment of the company's growth drivers and potential risks will be essential to determine whether current levels represent an attractive entry point.
EXEL’s Progress With Lead Candidate ZanzalintinibZanzalintinib is Exelixis' most important late-stage pipeline asset and represents the company's key growth driver as it seeks to diversify beyond its flagship cancer therapy, cabozantinib (marketed as Cabometyx). The next-generation oral investigational tyrosine kinase inhibitor (TKI) targets multiple pathways, giving it potential across several difficult-to-treat cancers.
The company's near-term investment thesis hinges on the regulatory outcome for zanzalintinib.
EXEL’s new drug application seeking approval of zanzalintinib in combination with Roche’s (RHHBY - Free Report) Tecentriq for the treatment of patients with metastatic colorectal cancer (mCRC) is under review in the United States. The targeted population includes patients who were previously treated with fluoropyrimidine-, oxaliplatin- and irinotecan-based chemotherapy, and, if they are RAS wild-type, an anti-epidermal growth factor receptor therapy.
The agency has set a target action date of Dec. 3, 2026.
A positive decision would mark the first approval for zanzalintinib and establish a new commercial growth platform beyond Cabometyx.
The company's recent disappointment stemmed from the final analysis of the dual primary endpoint of overall survival (OS) in the subset of patients without active liver metastases (non-liver metastases, NLM) in the late-stage STELLAR-303 study, evaluating zanzalintinib plus Tecentriq versus regorafenib in previously treated non-microsatellite instability (MSI)-high mCRC.
This showed a non-statistically significant trend in OS favoring the combination in the NLM subpopulation. Median OS was 15.9 months for patients treated with the combination therapy compared with 12.7 months for those receiving regorafenib.
The disappointing results are a setback in the company’s efforts to get approval for zanzalintinib.
Meanwhile, Exelixis continues to aggressively expand zanzalintinib's development program through strategic partnerships and multiple late-stage clinical studies.
The company recently broadened its collaboration with Merck (MRK - Free Report) to evaluate zanzalintinib in combination with subcutaneous Keytruda Qlex in the planned phase III STELLAR-316 study in patients with resected stage II/III colorectal cancer (CRC).
Exelixis will sponsor the study, while Merck will supply Keytruda Qlex. The study will evaluate zanzalintinib with and without Keytruda Qlex in patients with resected stage II/III CRC who, following definitive therapy, have tested positive for molecular residual disease (MRD+) and have no radiographic evidence of disease.
Exelixis has also partnered with Natera, a global leader in cell-free DNA and precision medicine, whose Signatera molecular residual disease assay will be used to identify eligible patients for STELLAR-316.
The Merck partnership extends beyond colorectal cancer. In April 2026, Merck initiated the phase III LITESPARK-034 trial evaluating zanzalintinib plus Welireg versus Welireg and placebo in previously treated advanced renal cell carcinoma (RCC) patients who progressed after PD-1/L1 and VEGFR-TKI therapies.
This marks the second Merck-sponsored phase III study under the collaboration, following LITESPARK-033 (launched in December 2025), which is assessing the combination against cabozantinib in first-line advanced RCC post-adjuvant immunotherapy.
These studies highlight Merck's confidence in zanzalintinib's potential across multiple RCC treatment settings while substantially expanding Exelixis' long-term growth opportunities.Beyond CRC and RCC, Exelixis is advancing additional indications for zanzalintinib through the planned phase II STELLAR-202 study in squamous non-small cell lung cancer and an expansion cohort in the ongoing phase Ib/II STELLAR-002 trial in metastatic castration-resistant prostate cancer. Success in any of these indications could significantly broaden the drug's commercial opportunity.
Roche’s Tecentriq is a cancer immunotherapy that is approved around the world, either alone or in combination with targeted therapies and/or chemotherapies, for various types of cancer.
EXEL’s Cabometyx Maintains MomentumLead drug Cabometyx is approved for advanced RCC and previously treated hepatocellular carcinoma.
In March 2025, Exelixis obtained FDA approval for the label expansion of Cabometyx for the treatment of adult and pediatric patients 12 years of age and older with previously treated, unresectable, locally advanced or metastatic, well-differentiated pancreatic and extra-pancreatic neuroendocrine tumors (pNET). The drug was also approved for adult and pediatric patients 12 years of age and older with previously treated, unresectable, locally advanced or metastatic, well-differentiated extra-pancreatic NET (epNET).
The Cabometyx franchise continued to gain momentum in 2026, maintaining its position as the leading prescribed TKI in renal cell carcinoma, the top TKI plus immunotherapy combination in first-line RCC, and the leading oral option in second-line and later neuroendocrine tumors.
Invest in EXEL StockWhile the STELLAR-303 results have tempered near-term expectations, zanzalintinib remains Exelixis' most most significant near-term catalyst. The upcoming FDA decision, multiple late-stage trials, and deepening collaborations with Merck and Natera provide several value-creating catalysts.
Positive regulatory and clinical outcomes could meaningfully diversify Exelixis' revenue base beyond Cabometyx and support the company's long-term growth trajectory.
We remain bullish on the stock's prospects and believe it offers additional upside potential. Accordingly, we view the shares favorably for prospective investors, while existing shareholders may consider maintaining their positions to capitalize on further growth opportunities.